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Gamma-Sarcoglycan Mediated Mechanotransduction in Skeletal Muscle
Abstract
Loss of gamma-sarcoglycan (g-SG) is common to both Duchenne and Limb Girdle muscular dystrophies,
and is sufficient to induce severe muscle degeneration and signaling defects in response to mechanical
load without causing susceptibility to contractile damage. This suggests that disease occurs not by
structural deficits, but through aberrant signaling, namely, disruption of normal mechanotransduction
signaling through the SG complex. However, the mechanisms of g-SG-mediated mechanical signaling are
poorly understood. Here, we identified the muscle-specific protein archvillin as a g-SG and dystrophic
interacting protein. Archvillin expression is dependent on g-SG, where levels are significantly unregulated
in human LGMD2C patient muscle and at the sarcolemma of murine g-SG-null (gsg-/-) muscle. However,
archvillin is delocalized in mdx muscle, indicating dystrophin-dependent sarcolemmal localization. In situ
eccentric contraction (ECC) of C57 mouse tibialis anterior (TA) muscles causes ERK1/2 phosphorylation,
nuclear activation of P-ERK1/2, and stimulus-dependent archvillin association with P-ERK1/2, whereas TA
muscles from gsg-/- and mdx mice exhibit heightened P-ERK1/2 and increased nuclear P-ERK1/2
localization following ECCs, but the archvillin-P-ERK1/2 association is completely ablated. These results
position archvillin as a mechanically sensitive component of the dystrophin complex, and demonstrate
that signaling defects caused by loss of g-SG occur both at the sarcolemma and in the nucleus. We also
extended our previous studies on mechanosensitive, g-SG dependent ERK1/2 phosphorylation to
determine whether additional pathways are altered with loss of g-SG. Using a passive stretching protocol
to isolate the effects of externally applied tension, we found that in isolated EDL muscles, Akt, S6RP, and
p70S6K activation increases with stretch in both C57 and gsg-/- isolated muscles. Treatment of muscles
with or without rapamycin during stretch blocks p70S6K activation in stretched C57 muscles, and reduces
downstream S6RP phosphorylation, indicating mTOR dependence. However, even though rapamycin
treatment decreases p70S6K activation in stretched gsg-/- muscles, S6RP phosphorylation remains
elevated. These results suggest that p70S6K is an important component of g-SG-dependent
mechanotransduction in skeletal muscle, where loss of g-SG uncouples the response of p70S6K to
stretch and implies that g-SG is important for inactivation of this pathway. In sum, this study
demonstrates altered load-sensing mechanisms in muscular dystrophies where the sarcoglycans are
absent.
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ABSTRACT
GAMMA-SARCOGLYCAN MEDIATED MECHANOTRANSDUCTION IN
SKELETAL MUSCLE
Janelle M. Spinazzola
Dr. Elisabeth R. Barton
Dr. H. Lee Sweeney
Loss of gamma-sarcoglycan (γ-SG) is common to both Duchenne and Limb
Girdle muscular dystrophies, and is sufficient to induce severe muscle degeneration and
signaling defects in response to mechanical load without causing susceptibility to
contractile damage. This suggests that disease occurs not by structural deficits, but
through aberrant signaling, namely, disruption of normal mechanotransduction signaling
through the SG complex. However, the mechanisms of γ-SG-mediated mechanical
signaling are poorly understood. Here, we identified the muscle-specific protein
archvillin as a γ-SG and dystrophic interacting protein. Archvillin expression is
dependent on γ-SG, where levels are significantly unregulated in human LGMD2C
patient muscle and at the sarcolemma of murine γ-SG-null (gsg-/-) muscle. However,
archvillin is delocalized in mdx muscle, indicating dystrophin-dependent sarcolemmal
localization. In situ eccentric contraction (ECC) of C57 mouse tibialis anterior (TA)
muscles causes ERK1/2 phosphorylation, nuclear activation of P-ERK1/2, and stimulusdependent archvillin association with P-ERK1/2, whereas TA muscles from gsg-/- and
mdx mice exhibit heightened P-ERK1/2 and increased nuclear P-ERK1/2 localization
following ECCs, but the archvillin-P-ERK1/2 association is completely ablated. These
results position archvillin as a mechanically sensitive component of the dystrophin
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complex, and demonstrate that signaling defects caused by loss of γ-SG occur both at the
sarcolemma and in the nucleus. We also extended our previous studies on
mechanosensitive, γ-SG dependent ERK1/2 phosphorylation to determine whether
additional pathways are altered with loss of γ-SG. Using a passive stretching protocol to
isolate the effects of externally applied tension, we found that in isolated EDL muscles,
Akt, S6RP, and p70S6K activation increases with stretch in both C57 and gsg-/- isolated
muscles. Treatment of muscles with or without rapamycin during stretch blocks p70S6K
activation in stretched C57 muscles, and reduces downstream S6RP phosphorylation,
indicating mTOR dependence. However, even though rapamycin treatment decreases
p70S6K activation in stretched gsg-/- muscles, S6RP phosphorylation remains elevated.
These results suggest that p70S6K is an important component of γ-SG-dependent
mechanotransduction in skeletal muscle, where loss of γ-SG uncouples the response of
p70S6K to stretch and implies that γ-SG is important for inactivation of this pathway. In
sum, this study demonstrates altered load-sensing mechanisms in muscular dystrophies
where the sarcoglycans are absent.
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CHAPTER 1: Introduction

1.1. Mechanotransduction in skeletal muscle
Skeletal muscle accounts for approximately 40% of human body weight and is
responsible for force generation, movement, and respiratory function. Not only does
skeletal muscle produce force, but it also has the capacity to sense changing workloads
and to respond and adapt to physiological demands to meet functional needs. When
deformation is imposed on a muscle, mechanical forces initiate changes in cellular and
molecular biochemical signals, known as mechanotransduction, altering muscle fiber
growth and survival, contractile properties, and metabolism. However, the mechanisms
by which mechanical forces acting through skeletal muscle cells generate intracellular
signaling are not fully understood.
Research has begun to characterize the sensors involved in relaying the
mechanical state of the muscle to the transcriptional and translational machinery during
contraction. Both passive stretch and active contraction impose stress on proteins
spanning the muscle plasma membrane (sarcolemma) through physical association with
the cytoskeleton and the extracellular matrix. In skeletal muscle, three glycoprotein
complexes transmit forces across the sarcolemma from the intracellular actin
cytoskeleton to the extracellular matrix during contraction: the dystrophin-glycoprotein
complex (DGC), the utrophin-glycoprotein complex (UGC), and the α7β1D integrin
complex. These complexes are thought to not only have structural function, but also
perform mechanical signaling functions critical to the development and maintenance of
skeletal muscle.
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1.2. The Dystrophin Glycoprotein Complex
The dystrophin glycoprotein complex (DGC) is a multimeric assembly of proteins
localized at the sarcolemma of skeletal, cardiac, and smooth muscle cells. Its composition
of transmembrane, cytoplasmic, and extracellular proteins varies slightly dependent on
the type of muscle. Two of the most highly conserved members of the DGC are the
dystroglycans (Lapidos et al., 2004). These two proteins are transcribed from a single
gene and are proteolytically cleaved to create α- and β-dystroglycan (Deyst et al., 1995).
Alpha-dystroglycan (α-DG) is localized at the plasma membrane and undergoes complex
glycosylation that enables its function as an extracellular matrix (ECM) receptor for

proteins including laminin, agrin, perlecan, and neurexin (Grewal et al., 2001;
Michele and Campbell, 2003). At the extracellular surface, the carboxyl-terminal
domain of α-DG binds the amino-terminal of β-dystroglycan (β-DG) (Di Stasio et al.,
1999), a single pass type-I transmembrane protein that is an integral core component of
the DGC. The carboxyl terminal domain of β-DG binds directly to multiple domain sites
of dystrophin within the cytosol (Jung et al., 1995; Rentschler et al., 1999; Rosa et al.,
1996).
Dystrophin is a 427 kDa cytoskeletal protein organized into four distinct domains:
an amino terminal actin-binding domain, a central rod domain with 24 homologous triple
helical repeats and four hinge domains, the cysteine-rich domain, and a COOH terminal
domain (Koenig et al., 1988). Through its association with actin and the carboxyl
terminus of β-DG via its cysteine-rich domain, dystrophin establishes a connection
between the cytoskeleton of muscle cells to the membrane bound portion of the DGC,
completing a continuous cytoskeletal-ECM linkage via the DGs to laminins (Rybakova
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et al., 1996; Sadoulet-Puccio and Kunkel, 1996). The C-terminus of dystrophin
associates with α-dystrobrevins and syntrophins, which bind neuronal nitric oxide
synthase (nNOS) (Ahn et al, 1996; Brenman et al, 196, Peter et al., 1997).
Another core component of the DGC are the sarocoglycans, which exist within
the DGC as a tetrameric subcomplex. Alpha-sarcoglycan (α-SG) (Bonnemann et al.,
1995; Roberds et al., 1993), beta-sarcoglycan (β-SG) (Bonnemann et al., 1995; Lim et al.,
1995), gamma-sarcoglycan (γ-SG) (Noguchi et al., 1995), and delta-sarcoglycan (δ-SG)
(Nigro et al., 1996) compose the SG complex in cardiac and skeletal muscle. In smooth
muscle, epsilon-sarcoglycan (ε-SG) (Ettinger et al., 1997) replaces α-SG to form a
unique complex (Straub et al., 1999), and zeta-sarcoglycan (ζ-SG), thought to be a
functional homologue of γ-SG, is expressed primarily in the brain (Shiga et al., 2006).
Associated with the SG complex is sarcospan, a quadruple-pass transmembrane protein
of the tetraspanin superfamily that also interacts with β-DG, thereby linking the SG
complex to the DGC core. The SG complex also binds to the N-terminus of dystrobrevin
(Yoshida et al., 2000). Together, the dystroglycans, sarcospan, dystrobrevin, syntrophins,
dystrophin, and the sarcoglycan complex form the DGC, a large complex that serves as
an important link between the cytoskeleton and the extracellular matrix surrounding
muscle cells. The significance of the DGC is made evident by the fact that mutations in
many of its components cause numerous muscle diseases, including several forms of
muscular dystrophy.
In the UGC, utrophin, the autosomal homolog of dystophin, replaces dystrophin
in the complex, with the other peripheral and integral membrane proteins retained.
Utrophin is expressed in several tissues where dystrophin is not such as lung and kidney,
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and in normal muscle, the UGC is primarily expressed at the neuromuscular junction
(Cartaud et al., 1992; Khurana et al., 1991). In muscles of dystrophin-deficient humans
and mice, utrophin expression increases (Khurana et al., 1991; Matsumura et al., 1992),
suggesting that the UGC is capable of compensating for the loss of the DGC at nonjunctional regions of the sarcolemma, which has been studied extensively as a potential
therapeutic strategy (Berthier and Blaineau, 1997; Deconinck et al., 1997b; Tinsley and
Davies, 1993).

Figure 1.1. The dystrophin glycoprotein complex
The dystrophin-glycoprotein complex (DGC) is an assembly of proteins localized at the
sarcolemma. Mutation in genes encoding various components of the DGC are associated
with several forms of muscular dystrophy.
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1.3. Muscular dystrophy
The muscular dystrophies are a group of hereditary, progressive muscle disorders
characterized by severe muscle weakness and eventual replacement of muscle tissue by
adipose and fibrotic connective tissue. There are several classifications of muscular
dystrophies that vary in severity, muscles affected, and genetic basis. Some of the most
common and severe forms of muscular dystrophy arise from mutation of genes encoding
components of the DGC, including Duchenne Muscular Dystrophy (DMD) and Limb
Girdle Muscular Dystrophies (LGMD) types 2C-F.

Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is an X-linked recessive disorder caused by out-offrame deletions of the largest human gene dystrophin. It affects approximately 1 in 3,500
male births (Hoffman et al., 1987), and is one of the most common and severe forms of
muscular dystrophy. Initial diagnosis is generally between 2-5 years of age when children
begin to demonstrate early hallmarks of the disease including delayed motor milestones
and enlarged calf muscles. DMD is characterized by repetitive cycles of muscle
degeneration and regeneration that eventually results in replacement of muscle with
adipose and fibrotic connective tissue such that the muscle no longer possesses forcegenerating capacity (Cros et al., 1989; Marshall et al., 1989). Thus, boys generally
become wheelchair-dependent between 10-12 years of age, and premature death occurs in
the late twenties to early thirties due to respiratory failure and cardiomyopathy (Nigro et
al., 1990). Advances in supportive care have improved quality of life and extended
lifetime considerably the last decade, but the next step must come from therapeutic
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approaches to ameliorate the underlying pathophysiology of DMD. Strategies to address
this will require a strong understanding of the genetic, biochemical, and cellular defects
that lead to muscle wasting in DMD.
Much of our knowledge about muscular dystrophy has come from studies of
animal models. The most frequently used animal model of DMD is the mdx mouse,
which carries a naturally occurring point mutation in exon 23 of the murine dystrophin
gene (Ryder-Cook et al., 1988). This mutation results in a premature stop codon and a
complete loss of dystrophin protein expression, and secondary loss of the entire DGC
complex from the sarcolemma (Hoffman et al., 1987). Mdx mice display severe fiber
degeneration, fibrosis and pathological changes in muscle that resemble DMD patients.
Despite this, however, compared with human DMD, mdx mice display much less severe
skeletal muscle and cardiac phenotypes, retain ambulation, and live approximately 80%
of normal lifespan (Chamberlain et al., 2007). Although the mdx mouse is not a perfect
model of the human disease, it has played a vital role in elucidating many of the
biochemical and cellular defects that contribute to the disease phenotype.

Limb Girdle Muscular Dystrophies 2C-F
Limb-Girdle muscular dystrophies (LGMD) types 2C-F are autosomal recessive
disorders caused by mutation of the γ-, α-, β-, δ-SG subunits, respectively, and most
severely affect the proximal muscles, including the shoulders, upper arms, pelvic area,
and thighs. The general characteristics of LGMD2C-F are similar to DMD, including
progressive muscle weakness and replacement of muscle with fibrotic tissue, but can vary
greatly in severity and age of onset, with an estimated prevalence of 1 in 10,000 to 1 in
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120,000 individuals (Bonnemann et al., 2002). Within LGMD 2C-F, LGMD2C is the
most severe and most closely resembles the disease progression and pathology of DMD
(Bonnemann et al., 2002; Nowak et al., 2000).
Mouse models of LGMD2C-F include the γ-SG-null mouse (gsg-/-) (Hack et al.,
1998), the α-SG-null mouse (asg-/-) (Duclos et al., 1998), the β-SG-null mouse (Durbeej
et al., 2000), and the δ -SG-null mouse (dsg-/-) (Hack et al., 2000). These models have
been utilized extensively to reveal the pathology associated with primary mutation of
each SG subunit. This is of interest given the observation that in LGMD or any of the SG
knock-out mice, upon loss of one sarcoglycan subunit, there is secondary loss or
reduction of the other sarcoglycans (Bonnemann and Finkel, 2002). Common
pathological features include muscle fiber degeneration and fibrosis, though there are
differences in the presentation of cardiac involvement (Politano et al., 2001)

1.4. Function of the DGC in muscle
The full scope of DGC function and the mechanisms by which mutation of its
components causes the pathology of muscle disease is not fully understood. Initially,
the DGC was thought to contribute a purely mechanical role in stabilizing the
sarcolemma during muscle contraction. However, growing evidence suggests that
components of the DGC also play significant signaling roles, that when absent, disrupt
signaling pathways involved in cell survival.

Mechanical role of the DGC
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making it susceptible to mechanical damage. The DGC is enriched at costameres,
transverse rib-like structures that overlie the z-line of the sarcomere, which are thought to
function in lateral force transmission from the sarcomere to the sarcolemma, the ECM,
and surrounding fibers in both skeletal (Rybakova et al., 2000) and cardiac muscle
(Danowski et al., 1992). Given its prime position, the DGC was initially thought to serve
a structural role, contributing to this strong mechanical link between the cytoskeleton and
the ECM.
Supporting this, early studies demonstrated that muscles of DMD patients (Mokri
and Engel, 1998) and mdx mouse muscle (Bulfield et al., 1984) have compromised
sarcolemma integrity, indicated by highly elevated levels of creatine kinase in DMD
patients, and uptake of Procion orange dye by mdx muscle, in particular following
contraction-induced injury (Moens et al., 1993; Petrof et al., 1993). Additionally, dye was
selectively taken up by muscle fibers that appeared necrotic, suggesting that increased
membrane permeability eventually resulted in cell death. These observations led to the
longstanding “mechanical defect” hypothesis that proposed that mutation in critical
structural components of the DGC compromise the mechanical stability of the
sarcolemma, exacerbating damage incurred during contraction that leads to death of the
myofiber (Cohn and Campbell, 2000; Hack et al., 1998; Petrof et al., 1993).
Indeed, it was later discovered that sarcolemmal tearing allowed leakage of
extracellular ions including calcium (MacLennan et al., 1991; Turner et al., 1991) into the
myofibers, causing activation of calcium-dependent proteases such as skeletal musclespecific calpains, resulting in degradation of muscle proteins and fiber degeneration
(Alderton and Steinhardt, 2000). This phenotype is further exacerbated with exercise
	
  

8

(Vilquin et al., 1998), but can be improved through immobilization (Mizuno, 1992;
Mokhtarian et al., 1999), indicating that the mechanical action of muscle stretch and
contraction is at least partially responsible for sarcolemmal damage that occurs in muscle
where the DGC is disrupted.
Characterization of the dystrophin homolog, utrophin, has also contributed to
revealing the mechanical functions of the DGC. Given utrophin’s structural similarity to
dystrophin and the discovery that mice lacking both utrophin and dystrophin
(mdx:utrophin) display a more severe phenotype than mdx mice that more closely mimics
the progression of DMD (Deconinck et al., 1997a), it was believed that the UGC may
perform redundant functions to the DGC. Both DMD patients and mdx mice have
upregulated utrophin expression that is further increased with exercise, leading to the
hypothesis that utrophin may be able to functionally replace dystrophin, acting in a
compensatory manner (Gordon et al., 2014; Khurana et al., 1991; Matsumura et al.,
1992). Indeed, introduction of full-length or trunctated forms of utrophin has been shown
to ameliorate dystrophy in mdx:utrophin double knockout mice, eliminating sarcolemma
degeneration and ion influx in response to mechanical stimulus, and improving
mechanical function (Deconinck et al., 1997b; Tinsley et al., 1998; Tinsley et al., 1996).
These data support a mechanical function for dystrophin and the DGC in
protecting the sarcolemma during muscle contraction, where in its absence, the
sarcolemma is more susceptible to damage, increasing the permeability of ions and small
molecules that ultimately results in cell necrosis and muscle degeneration. Although the
importance of the DGC in maintaining sarcolemma integrity is apparent, alternative
functions for this complex are becoming recognized, which may reveal mechanisms of
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disease where the DGC is compromised.
Although the DGC physically connects the cytoskeleton and the ECM and its
structural role in maintaining sarcolemma integrity suggests a primarily mechanical
function, these characteristics are also shared by well-known signaling molecules such as
cadherins and integrins (Cary et al., 1999; Wheelock and Johnson, 2003). The next
section describes the integrins as a basis for addressing the common and distinct features
of these complexes in muscle.

1.5. Mediators of signal transduction in muscle
The alpha7beta1D integrin complex – muscle’s classic mechanosensor
Integrins are glycoprotein heterodimers composed of one α-subunit and one βsubunit, each of which consists of a large extracellular domain, a single α-helical
transmembrane region, and a small intracellular C-terminal tail. In skeletal muscle,
α7β1D integrin is the major laminin binding integrin and is localized along the
sarcolemma, concentrated at costameres and neuromuscular junctions (Berthier and
Blaineau, 1997; Burkin and Kaufman, 1999). Similar to the DGC, α7β1D integrin plays a
critical role in maintaining stable connections between the actin cytoskeleton and laminin
in the ECM, (Boppart et al., 2006; Liu et al., 2012). In addition, α7β1D integrin functions
in signal transduction as a mechanoreceptor, serving as bidirectional outside-in and
inside-out signaling molecules (Hu and Luo, 2013; Hynes, 2002).
Unlike classic receptors, integrins do not have inherent kinase or enzymatic
activity. Instead, they rely on their association with non-receptor protein tyrosine kinases,
such as focal adhesion kinase (FAK), to relay information from the extracellular matrix to
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the cell nucleus. The activation of FAK also affects integrin association with several
other signaling proteins including Grb2, an adapter protein associated with the RasERK/MAP kinase pathway (Yang et al., 1995), and p85, which leads to activation of the
phosphatidylinositol 3-kinase (PI3K) pathway (Rando, 2001). Activation of these
pathways via integrins is associated with cell proliferation and survival (Stupack and
Cheresh, 2002). α7β1D integrin regulates activation of hypertrophy-associated molecules
including AKT, mTOR, and p70S6K (Boppart et al., 2006), and has been found to
negatively regulate MAPK activation associated with muscle damage following downhill
running. In addition, increasing α7β1 promotes muscle cell proliferation and prevents
apoptosis (Boppart et al., 2006; Gurpur et al., 2009; Liu et al., 2008). Thus, integrins not
only provide mechanical stability, but also transmit mechanical information into
biochemical signals that mediate muscle cell survival.
In skeletal muscle, deficiencies in integrin subunits lead to well-documented
signaling disruptions leading to muscle cell death and disease such as congenital
myopathy caused by mutation of the gene encoding the α7 subunit (Burkin and Kaufman,
1999; Hayashi et al., 1998; Vachon et al., 1997). Muscles of the mdx mouse and DMD
patients demonstrate elevated α7β1D integrin at the sarcolemma (Hodges et al., 1997),
thought to be a compensatory complex, which has initiated its investigation as a potential
therapeutic target. Overexpression of α7 integrin was found to ameliorate dystrophy in
mdx:utrophin double knockout mice, and expression of β1D integrin rescues the
cardiomyopathy of mdx mice (Burkin et al., 2005; Burkin et al., 2001; Liu et al., 2012),
suggesting that the integrin and dystrophin complexes have overlapping functions.
Interestingly, though, enhanced α7β1 integrin expression does not alleviate pathology in
	
  
11

δ-SG-null mice (Milner and Kaufman, 2007). Mice lacking both dystrophin and α7
integrin (mdx:α7-null) or γ-SG and α7 integrin develop severe muscular dystrophy and
die prematurely before one month of age (Allikian et al., 2004a; Guo et al., 2006; Rooney
et al., 2006). Similarly to integrins, dystrophin-glycoprotein complexes do not possess
any known inherent enzymatic activity. Thus, like integrins, the DGC could not only
serve as a mechanical link between the outside and inside of the cell, but could also serve
as an mechanosensor that converts mechanical information into biochemical signals that
ultimately lead to regulation of protein synthesis.

The DGC associates with signaling molecules
While the integrins may function as laminin-dependent signaling receptors in
skeletal muscle (Schwartz, 2010), whether the DGC similarly participates in downstream
signal transduction cascades is still under investigation. Growing evidence suggests that
the DGC not only has a structural role in muscle, but also functions as a mechanosensor
that initiates signaling cascades responsible for muscle maintenance. Studies of
dystroglycan function suggest that, similar to the functional binding of integrins to their
ECM ligands, binding of the dystroglycan complex to ECM proteins involves both
outside-in and inside out signaling (Hynes, 2002). For example, β-DG undergoes
adhesion-dependent tyrosine phosphorylation (James et al., 2000), enabling its binding to
the SH3 domain of Grb2 (Russo et al., 2000), an adapter protein involved in activation of
the MAPK pathway. This site is also where β-DG binds to dystrophin, suggesting that
phosphorylation at this site in β-DG may somehow cycle the interaction of β-DG with
either Grb2 or dystrophin. Preventing phosphorylation of β-DG improves the dystrophic
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phenotype of dystrophin deficient mice (Miller et al., 2012). In addition, inhibition of αDG expression or its binding to laminin-2 reduces the viability of myotubes in culture
(Brown et al., 1999; Montanaro et al., 1999). Similar to integrins, dystroglycans function
as scaffolds that mediate ERK signaling by acting as sites for ERK activation, directing
ERK signaling to or away from the nucleus, potentially influencing gene expression
(Spence et al., 2004). Thus, the association of the dystroglycans with Grb2 suggests that
the intracellular signaling pathways activated by integrins may also be activated in a
similar fashion by outside-in dystroglycan signaling.
In addition to the β-DG association with Grb2, initial evidence suggesting a
signaling role for the DGC is the association of nNOS with several DGC components in
skeletal muscle (Brenman et al., 1995). The significance of components of the DGC such
as sarcospan, dystrobrevins, and syntrophins that do not appear to have a direct or
essential role in the mechanical function of the DGC, but instead appear to be docking
sites for other intracellular signaling proteins (Haenggi and Fritschy, 2006), has fueled
considerable interest in what other intracellular pathways may be affected in DGCassociated muscular dystrophies. Given the association of dystrobrevins and syntrophins
with the carboxyl-terminus of dystrophin in the cytoplasm (Newey et al., 2000; SadouletPuccio et al., 1997), it was hypothesized that they may function as a scaffold for linking
nNOS to the DGC. nNOS is a signaling molecule involved in muscle contraction and
calcium dynamics, and also influences gene expression. nNOS is associated with the
DGC through tight binding with syntrophin (Adams et al., 2001; Miyagoe-Suzuki and
Takeda, 2001), which is also dependent on α-dystrobrevin, as demonstrated by the
absence of nNOS in α-dystrobrevin-null mice which display dystrophic symptoms
	
  

13

despite an otherwise intact DGC, suggesting that this interaction may be important for
nNOS function (Grady et al., 1999).

The significance of nNOS delocalization to dystrophy is a debated topic in the
field. Originally, the association of nNOS with the DGC led to the hypothesis that nNOS
gene targeting would cause a dystrophic phenotype similar to that observed with other
mutations of DGC components. However, knockout of nNOS does not cause overt
muscular dystrophy (Huang et al., 1993), nor does knockout of the syntrophins, which
also causes loss of nNOS from the sarcolemma (Adams et al., 2004; Kameya et al.,
1999). This suggests that the phenotype of the α-dystrobrevin knockout animals is not

attributable to the disruption of nNOS alone. Although alteration of the nNOSsyntrophin complex within the DGC does not cause muscular dystrophy, disruption of
nNOS does appear to alter other pathways such as muscle growth and regeneration
(Anderson, 2000; De Palma et al., 2014), and its overexpression ameliorates
inflammation and membrane injury in mdx muscle (Wehling et al., 2001). In addition,
enhancing nNOS activity through use of phosphodiesterase inhibitors has also been
shown to be attenuate functional muscle ischemia, injury, and fatigue following exercise
(Kobayashi et al., 2008).
While dystrophin was thought to serve a primarily mechanical role, its association
with non-mechanical DGC components elucidated its potential significance in muscle
signaling. Similarly, the DGC component sarcospan was initially thought to serve a
primarily mechanical role given that its overexpression leads to increased compensatory
utrophin and α7β1 integrin expression at the sarcolemma (Hodges et al., 1997) in
dystrophin-deficient muscle. Similar to integrins, sarcospan has been found to be a major
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regulator of Akt signaling pathways, where sarcospan-deficiency significantly impairs
Akt-mediated muscle regeneration via p70S6K following cardiotoxin injury (Marshall et
al., 2012). Sarcospan also regulates glycosylation of α-DG, which plays an important role
in its association with laminin and its outside-in signaling function (Nguyen et al., 2002).
Despite abundant evidence implicating components of the DGC in mediating
muscle signaling pathways, exactly how they regulate action of these signaling
molecules, and the relationship between these signaling and mechanical functions and
how their misregulation contributes to muscle disease is not fully understood.

1.6. Signaling pathways in muscle
Somewhat better understood are the downstream signaling pathways through
which mechanical stress affects gene expression in skeletal muscle that activate muscle
fiber size, contractile properties, and metabolism. These include the mitogen-activated
protein kinase (MAPK) pathway, which encompasses the extracellular regulated kinase
(ERK) family (Roux and Blenis, 2004a), the p38 family, and the c-Jun NH2 -terminal
kinase (JNK) family, as well as the phosphatidylinositol 3-kinase (PI3K) signaling
pathway, all of which are major effectors of mechanotransduction. Investigation of the
activation and regulation of these signaling pathways has revealed an emerging role for in
the disease progression in muscular dystrophies.

MAPK pathway
In skeletal muscle, mechanical deformation initiates MAPK activation through
tyrosine and threonine phosphorylation events by upstream MAPK kinases. For example,
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mechanical events initiate sequential phosphorylation of Raf, MEK, and finally ERK.
Critical in the activation of receptor tyrosine kinases and activation of Raf is Grb2, the
signal transducer and adaptor protein previously mentioned to strongly associate with the
DGC. Ultimately, ERK phosphorylates a number of cytoplasmic targets, including PLA2,
p90RSK, and MAP kinase activated protein kinases. Activated ERK also translocates to
the nucleus and phosphorylates several transcription factors involved in cell survival and
proliferation, including c-Myc, c-Jun, c-Fos, and Elk-1 (Davis, 1995; Garrington and
Johnson, 1999), thereby regulating gene expression. ERK phosphorylation has been
reported in response to tetanic muscle contraction (Martineau and Gardiner, 2001; Ryder
et al., 2000) as well as passive stretch alone (Wretman et al., 2001), and this activation
has been shown to be positively correlated with tension, where eccentric contraction
elicits the strongest ERK activation, followed by isometric contraction, concentric
contraction, and passive stretch (Martineau and Gardiner, 2001). Myotubes from gsg-/mice show increased apoptosis with concomitant activation of ERK1/2 compared to the
myotubes prepared from wild-type mice, with activation of ERK1/2 further increased
upon application of mechanical stretch (Griffin et al., 2005). In whole EDL muscles from
mdx and gsg-/- mice, ERK1/2 activation is aberrant both at rest and in response to ex vivo
mechanical stimulation (Barton, 2006), indicating potential misregulation of its target
transcription factors. Therefore, the ERK signaling pathway has the potential to be a
central mediator of muscle mechanotransduction, integrating mechanical, metabolic, and
activity signals.
The JNK pathway is associated with mediating cell differentiation, proliferation,
and apoptosis through activation of its downstream targets, including c-Jun, Elk1, and
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p53. JNK exists in p46 and p54 isoforms, both of which are mechanosensitive, and its
activation is proportional to tension (Martineau and Gardiner, 2001). Grb2 is involved in
recruiting the p46 isoform of JNK, which binds syntrophins (Hasegawa et al., 1999) and
promotes cell survival (Chamberlain and Rando, 2006; Oak et al., 2001). JNK is highly
activated in skeletal and cardiac muscle of mdx mice, and expression of the JNK
inhibitory protein, JIP1, ameliorates dystrophic pathology in these mice, suggesting that
JNK1 contributes to muscle pathogenesis in mdx mice (Kolodziejczyk et al., 2001). Of
note, ERK1/2 is hyperactivated in younger mice (Kumar et al., 2004), whereas JNK
hyperactivation is more pronounced in old mice (Kolodziejczyk et al., 2001) suggesting
that variable MAPK are activated at different disease stages and may contribute to
disease onset and/or progession differentially. In support of this, expression of
constitutively active JNK causes compromised integrity and cell death in cultured
myotubes (Kolodziejczyk et al., 2001). However, disruption of the interaction between αDG and laminin causes decreased JNK p54 activation as well as decreased activation of
its downstream target c-Jun and apoptosis (Oak et al., 2003). Overall, these results
suggest that there is a narrow window of effective JNK signaling, and that its
misregulation may contribute to the pathology of muscular dystrophy.
p38 MAPK signaling mediates skeletal muscle development and maturation, and
is associated with the DGC through binding to α-syntrophin (Hasegawa et al., 1999). The
most highly expressed isoform in skeletal muscle is p38α, which can affect myoblast
fusion to form myotubes (Cuenda and Cohen, 1999; Lechner et al., 1996), and influence
activation of transcription factors including MEF2 and MyoD (Keren et al., 2006). The
direct role of p38 in the pathogenesis of muscular dystrophy is unclear, although it is
	
  

17

known to be misregulated in mdx mice muscle. Interestingly, in mdx diaphragm, which
exhibits the most severe dystrophic phenotype, p38 activation is significantly reduced,
whereas p38 activation is normal in the more mildly affected limb muscles from the same
mice (Lang et al., 2004). Given this observation, the effect of upregulating p38 activity
has been investigated in several dystrophic mouse models. Activation of p38 signaling
has been found to increase utrophin expression in mdx diaphragm (Amirouche et al.,
2013) as well as in sarcospan-null mice muscle with improved muscle repair following
cardiotoxin injury (Marshall et al., 2012). Mice lacking Dusp10, a negative regulator of
p38 and JNK, showed attenuated dystrophic pathology in mdx muscle suggesting that p38
signaling is protective (Shi et al., 2013). However, there is now contrasting evidence of
p38 hyperactivity in dystrophic muscle contributing to pathology. Deletion of MAPK14
(p38α-encoding gene) in the skeletal muscle of mdx or dsg-/- mice was found to reduce
pathology, and transgenic mice with heightened muscle-specific p38α signaling presented
with severe myofiber necrosis and many hallmarks of muscular dystrophy due to p38
specific phosphorylation of the cell death protein Bax. Further, treatment of dsg-/- mice
with a p38 inhibitor has also been found to reduce disease (Wissing et al., 2014).
Therefore, similar to JNK, both over-activation and under-activation of p38 may cause
dystrophic pathology, suggesting that proper tuning of p38 activity is critical for healthy
muscle.

PI3K/Akt pathway
The Akt family of serine/threonine-specific protein kinases are activated through
several receptor tyrosine kinases associated with the phosphoinositide 3-kinase (PI3K)
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pathway. Signaling through the PI3K/Akt cascade leading to downstream activation of
p70S6K protein synthesis pathways is important for regulation of muscle strength,
hypertrophy, and promotion of cell survival (Otto and Patel, 2010). Akt induces skeletal
muscle hypertrophy in vitro and in vivo through activation of the mammalian target of
rapamycin (mTOR) pathway (Bodine et al., 2001; Pallafacchina et al., 2002), which
phosphorylates p70S6K (Isotani et al., 1999). Like the MAPK pathways, the PI3K/Akt
pathway can interact with the DGC via Grb2 (Leshem et al., 2002).
Disruption of dystroglycan binding to laminin causes PI3K/Akt-mediated
apoptotic cell death in muscle cells (Langenbach and Rando, 2002), suggesting a
significant role for reduced PI3K/Akt signaling in the dystrophic process. Akt signaling is
elevated in DMD patient biopsies as well as mdx and dsg-/- dystrophic mouse models, and
it is proposed that that this elevated Akt activity functions to activate p70S6K in an
attempt to increase protein synthesis for myofiber regeneration (Peter and Crosbie, 2006).
This hypothesis is supported by evidence showing that over-expression of constitutively
active Akt in mdx mice results in upregulation of utrophin and a7βl integrin, which leads
to improvement in force generation (Kim et al., 2011; Peter et al., 2009). Over-expression
of α7 integrin has also been shown to increase Akt signaling and p70S6K protein
synthesis (Boppart et al., 2011). Similarly, overexpression of sarcospan has been shown
to stabilize the UGC and α7β1 integrin at the sarcolemma in mdx mice, activate Akt and
downstream p70S6K, and ameliorate dystrophic pathology (Marshall et al., 2012). Taken
together, these studies suggest an important role for reduced PI3K/AKkt signaling in the
dystrophic process and as a therapeutic target. Differential activation of Akt and p70S6K
in C57 and gsg-/- muscle in response to mechanical perturbation will be discussed in
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Chapter 3.

1.7. The sarcoglycans in skeletal muscle
The sarcoglycans (SGs) are a family of homologous transmembrane proteins with
single membrane spanning domains (Ozawa et al., 1998). Six sarcoglycan genes have
been identified, each of which transcodes a separate sarcoglycan protein: α-, β- δ-, ε-, γ-,
and ζ-SG. α-SG and ε-SG share high homology and are type I transmembrane proteins,
whereas β-, γ-, δ-, and ζ-SG are type II transmembrane proteins. β-SG shares weak
homology with γ- and δ-SG. In cardiac and skeletal muscle, α-, β- δ-, and γ-SG form a
tetrameric complex with a 1:1:1:1 stoichiometry (Jung et al., 1995). The complex
assembles in the endoplasmic reticulum, where δ-, β-, and γ-SG form a core unit to which
α-SG binds (Shi et al., 2004). The complex also co-assembles with β-DG, although this
interaction is less well studied (Chan et al., 1998).
As mentioned previously, autosomal recessive mutations in γ-, α-, β-, δ-SG
subunits cause LGMD types 2C-F, respectively, and in both humans and mouse models,
mutation of a single SG subunit is associated with differential secondary loss or reduction
in sarcolemmal expression of the other subunits. For example, in the absence of δ-SG, α-,
β-, and γ-SG are quickly degraded before transport from the Golgi and are therefore
undetectable at the sarcolemma, whereas upon loss of γ-SG, α-SG is still detectable,
albeit at reduced levels (Chen et al., 2006; Hack et al., 2000; Hack et al., 1998; Shi et al.,
2004). SG-null mice begin to display dystrophic symptoms at about two weeks of age,
including necrosis, immune cell infiltration, fibrosis, and compromised force generation,
with variable cardiac involvement (Coral-Vazquez et al., 1999; Durbeej et al., 2000).
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Function of the sarcoglycan complex
Structural/mechanical function
The role of the sarcoglycan complex alone and as a component of the DGC is not
well-defined,	
  but like the DGC itself, the complex appears to have both mechanical and
signaling roles. Given its position at the sarcolemma, it was initially thought that the
sarcoglycan complex may have a role in stabilizing the DGC. There is a strong
association between the sarcoglycan complex and the dystroglycans, though it is
unknown whether the sarcoglycan complex binds directly to α-DG, β-DG, both, or
possibly through co-interaction with sarcospan (Chan et al., 1998; Marshall and CrosbieWatson, 2013; Straub et al., 1998). Loss of the sarcoglycan complex results in increased
sensitivity of β-DG to cleavage by a matrix metalloproteinase (MMP) disrupting the
linkage of the cytoskeleton to the ECM (Yamada et al., 2001). In addition, muscular
dystrophies that retain the SG complex do not have cleavage of β-DG, suggesting that
physical access to the cleavage site on β-DG by the MMP may be necessary, and the
presence of the SG complex inhibits this access. (Matsumura et al., 2005). In the BIO
14.6 Syrian hamster model with primary δ-SG mutation, biochemical analysis reveals
that dystroglycan no longer associates with the SG complex (Straub et al., 1998).
In addition to association with β-DG, further evidence that the SGs are involved
in DGC stabilization is that the C-terminus of dystrophin appears to directly interact with
δ and β-SG in COS- 1 cells, though this interaction appears to be weak (Chen et al.,
2006). It is possible that dystrophin binds a fully assembled sarcoglycan complex with
greater affinity in vivo. However, the association of dystrophin with the DGC does not
depend on the SGs, as SG-null mice express normal levels of dystrophin at the
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sarcolemma (Hack et al., 2000; Hack et al., 1998). This observation suggests that the SG
complex may have an essential function in muscle independent of the primarily
mechanical role of dystrophin.

Mechanosensor/signaling function
Growing evidence suggests that the SG complex is involved in
mechanotransduction. The intracellular regions of α- β- and γ-SG have potential tyrosine
phosphorylation sites, and in cell culture studies, adhesion gives rise to phosphorylation
of each of these SGs, indicating an attachment-dependent modification, and suggesting
that the SG complex may participate in the outside-in signaling of the DGC (Yoshida et
al., 1998). The adhesion-dependent tyrosine phosphorylation of α- and γ-SG, possibly by
FAK (Yoshida et al., 1998), is analogous to the tyrosine phosphorylation events
associated with the outside-in signaling that occurs in response to integrin interactions
with extracellular matrix proteins (Schwartz, 2010). The association of the DGC with
focal adhesion proteins such as β1 integrin and FAK is modulated by α-SG expression,
and the recruitment of these proteins to focal adhesion sites is central to integrinmediated cell survival signaling (Yoshida et al., 1996). The SG complex may also be
involved in the inside-out signaling of the DGC involving α5β1 integrin, which
associates with a dystrophin-containing lattice structure during muscle development
(Lakonishok et al., 1992). Downregulation of either α-SG or γ-SG reduces α5β1 integrinmediated muscle cell adhesion and focal adhesion formation (Yoshida et al., 1998). Thus,
the affinity of the DGC for its ECM ligand, laminin, may be modulated by other
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components of the complex, reminiscent of inside-out signaling of integrins (Disatnik and
Rando, 1999).
The SG complex is associated with the N-terminus of dystrobrevin, suggesting
that the SG complex is linked to the signaling protein nNOS via α-syntrophin associated
with dystrobrevin (Yoshida et al., 2000). Therefore, the signaling defects that have been
proposed to underlie muscular dystrophies associated with SG and dystrobrevin
mutations may involve these pathways (Grady et al., 1999). Similarly to mdx mice,
sarcolemmal localization of nNOS is also lost in the mouse models of SG deficiency as
well as sarcoglycanopathy patients (Crosbie et al., 2002). However, it has not been shown
that the SGs directly alter nNOS-mediated signaling activity.

Gamma-sarcoglycan and disease
Gamma-sarcoglycan is a 35 kDa member of the SG complex highly expressed in
skeletal, cardiac, and smooth muscle. It is transcoded by the SGCG gene located on
chromosome 13q12. There have been at least 5 naturally occurring variants and
mutations identified in the SGCG gene causing limb-girdle muscular dystrophy type 2C,
(Bonnemann and Finkel, 2002; McNally et al., 1996). The most common mutation,
Δ521-T, results in a frameshift and premature stop codon, and an unstable truncated
protein that causes severe DMD-like muscular dystrophy (Eiris-Punal et al., 2002). Of
notable interest is the report of a patient with primary γ-SG mutation resulting in a
truncated γ-SG protein absent from the sarcolemma, yet the other three SGs were
appropriately expressed and localized to the sarcolemma as was the rest of the DGC.
Despite the preservation of nearly the entire DGC, the patient had a severe muscular
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dystrophy (Crosbie et al., 2000). This finding suggests that γ-SG is critical for muscle cell
survival and possibly a functional interaction with a yet to be identified ligand.
The cytoplasmic domains of γ- as well as δ-SG bind directly to the actincrosslinking protein filamin C, which is found at both the Z-band and plasma membrane
of muscle. Mutation in the Filamin C gene causes human myopathy with cardiac
involvement (Furst et al., 2013). Filamin C has been found to be essential in maintaining
sarcolemmal integrity during force generation, and is involved in actin reorganization and
signal transduction cascades associated with force transduction and cell survival (Dalkilic
et al., 2006; Feng and Walsh, 2004; Razinia et al., 2012). In response to the loss of the
SG complex, expression of filamin C is significantly upregulated, its distribution
concentrated primarily at the plasma membrane (Thompson et al., 2000), though its
potential as a compensatory mechanism has not yet been explored.
The LGMD2C γ-SG-null mouse (gsg-/-) was generated by gene targeting of exon
2 and exhibits an additional loss of β- and δ-SG and decrease of α-SG expression at the
sarcolemma. Normal levels of dystrophin remain localized at the plasma membrane, as
do the others members of the DGC with the exception of sarcospan (Hack et al., 1998).
Mice lacking γ-SG display muscle weakness, fiber degeneration, and fibrosis similar to
LGMD2C patients. Early generations of gsg-/- mice (C57BL/6 background) displayed
severe cardiomyopathy that led to premature mortality at 20 weeks (Hack et al., 1998);
however, terminal cardiac defects have since been bred out of this line.

Emerging role for γ -SG in mechanotransduction
Initial evidence suggesting γ-SG to be a mechanosensor included studies
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demonstrating its stimulus-dependent phosphorylation. In cell culture studies, the
intracellular domains of γ-SG as well as α-SG were found to be tyrosine phosphorylated
in response to cell adhesion, possibly by FAK (Yoshida et al., 1998). Subsequent studies
in mice showed that γ-SG is tyrosine phosphorylated in hindlimb muscle following ex
vivo eccentric contraction (Barton, 2006). Given this stimulus-dependent modification,
the influence of γ-SG in mediated downstream ERK signaling was analyzed. Gsg-/- mice
display aberrant P-ERK1/2 activation both at rest and with mechanical stimulation
(Barton, 2006), indicating that γ-SG plays a role in signal transduction. However, further
investigation demonstrated that γ-SG sarcolemmal localization alone is not sufficient to
mediate normal signaling, and that phosphorylation of the γ-SG tyrosine 6 residue is
required to preserve normal ERK signal transduction patterns (Barton, 2010). The role of
γ-SG in mediating mechanosensitive signaling will be discussed in Chapters 2 and 3.

Does a signaling defect contribute to muscular dystrophy pathology?
Loss of dystrophin and/or sarcoglycan results in different mechanical
consequences, which suggests there are alternative mechanisms leading to muscle
degeneration. Dystrophin mutations produce a secondary reduction of the sarcoglycan
subunits; therefore, SG deficiency is a feature seen in both DMD and in the mdx mouse.
In the mdx mouse, there is clearly a mechanical defect, where there is a significant loss in
force-generating capacity and sarcolemmal degeneration following mechanical
stimulation. In contrast, gsg-/- mice, which retain dystrophin, do not display these deficits,
yet still develop fiber degeneration and fibrosis comparable to mdx mice (Hack et al.,
1999). Thus, a non-mechanical, perhaps signaling mechanism, may contribute to the
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phenotype in muscle with primary SG deficiency as well with primary dystrophin
deficiency, highlighting that the SG complex plays more than just a mechanical
stabilizing role.
Recently, canonical TGFβ signaling was found to be upregulated in gsg-/- muscle
following ex vivo eccentric contraction, with rapid accumulation of nuclear
phosphorylated SMAD, which mediates fibrosis in cardiac and skeletal muscle. By
introducing a heterozygous mutation of SMAD4 into gsg-/- mice to reduce but not ablate
SMAD4, Goldstein et al showed that these mice had improved body mass, cardiac
function and improved tetanic force (Goldstein et al., 2014). Thus, γ-SG may mediate
multiple mechanosensitive signaling pathways that are disrupted in its absence and cause
dystrophic pathology.
In summary, the contribution of mechanical transduction pathways to muscle
adaptation is particularly pertinent to the manifestation of muscle disease. Current data
provide substantial evidence that γ-SG is involved in mediating mechanotransduction in
skeletal muscle. However, more work is necessary to identify the mechanisms by which
this occurs. To this end, the experiments presented in this dissertation are aimed at testing
the hypothesis that γ-SG associates with mechanically sensitive signaling proteins, where
understanding of their interaction will help identify the mechanisms underlying
mechanical signal transduction disrupted in muscle diseases.
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CHAPTER 2: Gamma-sarcoglycan is Required for the Response of Archvillin to
Mechanical Stimulation in Skeletal Muscle

This chapter is adapted from:
Janelle M. Spinazzola, Tara C. Smith, Min Liu, Elizabeth J. Luna, Elisabeth R. Barton.
γ-SG is required for the response of archvillin to mechanical stimulation in skeletal
muscle. Human Molecular Genetics (2015) (Epub ahead of print)

This work was supported by National Institute of Health Grants U54 AR052646 to
E.R.B., R01 GM033048-26S1 to E.J.L. and T32 AT-052461 to J.M.S.
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2.1. Summary
Loss of gamma-sarcoglycan (γ-SG) induces muscle degeneration and signaling
defects in response to mechanical load, and its absence is common to both Duchenne and
limb girdle muscular dystrophies. Growing evidence suggests that aberrant signaling
contributes to the disease pathology; however, the mechanisms of γ-SG-mediated
mechanical signaling are poorly understood. To uncover γ-SG signaling pathway
components, we performed yeast two-hybrid screens, and identified the muscle-specific
protein archvillin as a γ-SG and dystrophin interacting protein. Archvillin protein and
message levels were significantly upregulated at the sarcolemma of murine γ-SG-null
(gsg-/-) muscle, but delocalized in dystrophin deficient mdx muscle. Similar elevation of
archvillin protein was observed in human quadriceps muscle lacking γ-SG.
Reintroduction of γ-SG in gsg-/- muscle by rAAV injection restored archvillin levels to
that of control C57 muscle. In situ eccentric contraction of tibialis anterior (TA) muscles
from C57 mice caused ERK1/2 phosphorylation, nuclear activation of P-ERK1/2, and
stimulus-dependent archvillin association with P-ERK1/2. In contrast, TA muscles from
gsg-/- and mdx mice exhibited heightened P-ERK1/2 and increased nuclear P-ERK1/2
localization following eccentric contractions, but the archvillin-P-ERK1/2 association
was completely ablated. These results position archvillin as a mechanically sensitive
component of the dystrophin complex, and demonstrate that signaling defects caused by
loss of γ-SG occur both at the sarcolemma and in the nucleus.
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2.2. Introduction
Skeletal muscle mechanotransduction is mediated in part by the dystrophin
glycoprotein complex (DGC), an assembly of proteins that also maintains the integrity of
the sarcolemma by linking the cytoskeleton and the extracellular matrix (Ervasti and
Sonnemann, 2008; Lapidos et al., 2004). Mutations in genes encoding DGC components
cause several forms of muscular dystrophy including limb girdle muscular dystrophies
(LGMD) types 2C-F from mutation of γ-, α-, β-, and δ-SG subunits of the sarcoglycan
(SG) complex, as well as Duchenne muscular dystrophy (DMD) from mutation of
dystrophin. Upon loss of dystrophin in DMD patients and in the mdx mouse model for the
disease, there is a secondary loss of the entire DGC including the sarcoglycans. However,
with primary mutations in any of the sarcoglycans, only presence of the SG complex is
compromised, with retention of dystrophin and other DGC components (Durbeej and
Campbell, 2002; Engel and Franzini-Armstrong, 2004). This holds true for the LGMD2C
γ-SG null mouse model (gsg-/-), where there is secondary reduction or absence of the
other three sarcoglycan subunits. Dystrophin loss in skeletal muscle causes compromised
force-generating capacity and contraction-induced damage with sarcolemmal tearing and
fiber degeneration (Hack et al., 1998; Petrof et al., 1993), which are thought to be
primary contributors to the progressive loss of muscle and its replacement with fat and
fibrotic tissue (Engel and Franzini-Armstrong, 2004). In contrast, there is a different
progression to disease in LGMD2C, where skeletal muscles from gsg-/- mice display little
contraction-induced damage early in life, yet still develop a similarly severe pathology
(Hack et al., 1999; Hack et al., 1998), indicating that γ-SG deficiency alone is sufficient
to induce several dystrophic symptoms. Based on this separation between mechanical
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fragility and dystrophic pathology, we and others have asserted that loss of the SG
complex disrupts proper load sensing in muscle, which then leads to muscle disease.
Previous work in our lab demonstrated that sarcolemmal localization of γ-SG and
phosphorylation of its tyrosine 6 residue is essential for normal extracellular signalregulated kinase 1 and 2 (ERK1/2) signaling in muscle subjected to eccentric contraction
(ECC) (Barton, 2010), and that loss of γ-SG also uncouples the response of the p70S6K
pathway to passive stretch (Moorwood et al., 2014). These results support that γ-SG is an
important component of the normal signaling profile in response to mechanical
perturbation. However, the mechanisms by which γ-SG mediates mechanical signal
transduction are unknown. Because of the importance of γ-SG as a mechanosensor in the
absence of any known endogenous enzymatic activity, and the fact that the sequence of
its intracellular domain is also critical for normal ERK1/2 signaling, we hypothesized that
γ-SG must transmit load-induced signals to downstream pathways via association with
binding partners.
Based on this premise, we performed a yeast two-hybrid assay to identify
potential binding partners for the intracellular domain of γ-SG, and an intriguing
candidate, archvillin, emerged. Archvillin is a 250kDa muscle-specific isoform of
supervillin, a known actin- and myosin-II-binding protein (Chen et al., 2003; Oh et al.,
2003). Although a series of yeast two-hybrid and proteomics analyses have identified
interactors for nonmuscle supervillin isoform 1 (NP_003165.2) (Nebl et al., 2002; Smith
et al., 2010; Smith et al., 2013; Takizawa et al., 2007; Takizawa et al., 2006), interaction
partners have not been reported for the differentially spliced, muscle-specific insert of
amino acids 276-669 in archvillin, which are encoded by coding exons 3, 4, and 5 (Oh et
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al., 2003). Thus, even though archvillin is abundantly expressed in cardiac and skeletal
muscle (Pope et al., 1998), its role in striated muscle has not been identified. Colocalization at the sarcolemma with dystrophin in hamster skeletal muscle (Oh et al.,
2003) suggests that archvillin may serve some function in the DGC, but this has not been
confirmed. A related isoform, smooth muscle archvillin (SmAV), has been shown to be
an ERK scaffolding protein that associates with ERK in a stimulus-dependent manner in
aortic tissue stimulated with the alpha agonist phenylephrine (Gangopadhyay et al., 2009;
Gangopadhyay et al., 2004). However, ERK association with the striated muscle
archvillin has not been demonstrated to date. Given the known sarcolemmal localization
of archvillin, its identification in yeast two-hybrid screens with γ-SG and dystrophin, as
well as the ability of the smooth muscle isoform to associate with ERK, the goal of this
study was to determine if archvillin is part of the mechanical signaling machinery in
skeletal muscle.
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2.3. Results
Archvillin interacts with γ -SG and dystrophin
To identify binding partners of γ-SG, we performed a yeast-two hybrid assay in
which we cloned the intracellular domain of human γ-SG into a pGBKT7 bait plasmid
and screened it against a normalized human library. Prey fragments of bait-prey positive
interaction colonies were PCR amplified and identified using the BLAST algorithm and
included archvillin, the β-sarcoglycan subunit of the sarcoglycan complex, as well as
vesicle trafficking proteins (Table 2.1, Supplementary Table 2.1). We identified two
identical prey clones encoding the extreme C-terminus of archvillin (aa 2093-2214)
(Figure 2.1A), and this fragment was re-transformed into the prey yeast strain for
confirmation of the interaction with γ-SG by two methods (Figures 2.1B, 2.1C). First, we
performed a binding assay in which yeast containing either the γ-SG/pGBKT7 bait
plasmid or empty pGBKT7 plasmid were re-mated with yeast containing the archvillin
prey sequence identified in the initial yeast two-hybrid screen, assuring that mated yeast
contained both bait and prey plasmids. Mated yeast were plated on selective dropout
media plates containing x-α-gal, where positive interaction would activate βgalactosidase expression and yield blue colonies. Yeast mated containing the γSG/pGBKT7 plasmid yielded blue colonies, whereas yeast mated containing the negative
control empty pGBKT7 plasmid did not grow any colonies on the most stringent
quadruple drop-out plates (Figure 2.1B). Second, co-immunoprecipitation (co-IP) with
anti-γ-SG was performed on skeletal muscle extracts from wild type (C57) and gsg-/mice, followed by immunoblotting with anti-archvillin or anti-γ-SG. In samples from C57
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mice, bands for both γ-SG and archvillin were observed following co-IP (Figure 2.1C,
lane 3), whereas co-IP could not pull down archvillin in samples lacking γ-SG even
though there was abundant archvillin in the lysate (Figure 2.1C, lane 2, 4). Biochemical
confirmation of the archvillin interaction with γ-SG was attempted, but the experiments
were unsuccessful due to insolubility of the tagged γ-SG cytoplasmic domain (data not
shown). Thus, the interaction between the intracellular portion of γ-SG and the Cterminus of archvillin identified by the yeast two-hybrid screen was sufficient to afford
physical association between these proteins in skeletal muscle, but whether this was a
direct interaction between the domains of these proteins or an indirect association via
intermediate proteins is unknown.
We also used yeast two-hybrid screening and co-sedimentation assays to show a
direct interaction between archvillin and dystrophin (Table 2.1, Figure 2.1D). In a
separate yeast two-hybrid screen, the bait was the differentially spliced first musclespecific sequence (aa 277-669) of human archvillin. Thirty unique prey clones from 14
identified interactors were confirmed from this screen (Table 2.1). Five unique
dystrophin clones were identified that spanned rod domains 8-13 (aa 1239-1724), as well
as two unique clones spanning rod domains 9-13 of the dystrophin ortholog utrophin (aa
1284-1715), with rod domains 11-12 present in all dystrophin and utrophin clones
(Figure 2.1A). Other prominent prey fragments from the screens with the archvillin bait
were from nexilin and myosin binding protein C, which also play a role in maintaining
sarcomeric integrity (Table 2.1). We confirmed the archvillin-dystrophin interaction by
co-sedimenting purified recombinant His-tagged dystrophin spectrin repeat domains 1012 (His-DMD-10-12) with purified GST-tagged archvillin protein fragments. His-DMD	
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10-12 was pulled down with the muscle-specific archvillin sequences encoded by exons
3-5 (GST-AV-277-669), but did not co-sediment with either GST-AV-1-171 or GST
alone (Figure 2.1D). Thus, based on two independent yeast-two hybrid screens and
subsequent co-IP/co-sedimentation experiments, the muscle-specific insert of archvillin
binds to dystrophin, and its interaction with γ-SG impacts its association with the DGC.
These interactions are schematized in Figure 2.1A.
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Bait

γ-SG
aa 1-35

hAV
aa 227669c

Interactors
Archvillin (SVIL)a
Coatomer subunit delta isoform 2
(COPD2)
Beta-sarcoglycan (SGCB)
PDZ and LIM domain protein 2
isoform 2 (PDLIM2)
Nexilin (NEXN)

Accession Number
Protein
Nucleotide
NP_003165.2
NM_003174.3

Number of Clones
Total
Individual
2
1

NP_001135753.1

NM_001142281.1

2

1

NP_000223.1

NM_000232.3

1

1

NP_067643.3

NM_021630.5

1

1

NP_001165780

NM_001172309.1

15

6

Myosin binding protein C (MYBPC1)
Dystrophin (DMD)
Utrophin (UTRN)
Basic helix-loop-helix family member
e40 (BHLHE40)
Lamin A/C (LMNA)
A kinase anchor protein 9 (AKAP9)

NP_996555
NP_004001
NP_009055

NM_206819
NM_004010
NM_007124

8
8
2

6
5b
2

NP_003661

NM_003670

2

1

NP_733822
NP_005742

NM_170708
NM_005751

2
1

1
1

Acyl-CoA binding domain containing 3
(ACBD3)
Collagen, type VI, alpha 3 (COL6A3)

NP_476507

NM_022735

1

1

NP_001120959

NM_057166

1

1

Filamin C, gamma (FLNC)
Kelch-like family member 7 (KLHL7)
Kinesin family member 1C (KIF1C)
Protein inhibitor of activated STAT, 1
(PIAS1)
Trio Rho guanine nucleotide exchange
factor (TRIO)

NP_006603
NP_061334
NP_073572

NM_001127487
NM_018846
NM_006612

1
1
1

1
1
1

NP_057250

NM_016166

1

1

NP_009049

NM_007118

1

1

Table 2.1. Candidate binding partners for human γ-SG intracellular domain aa 1-35
and hAV muscle specific insert 1 aa 277-669.
Positive interactors were identified in two yeast two-hybrid screens. Names, protein and
nucleic acid accession numbers, and the numbers of total and unique clones for each
interactor are shown. a Archvillin was confirmed as a γ-SG aa 1-35 interactor by
secondary assays. b Two of the identified dystrophin clones had incomplete sequencing
results, and were thus included in the count of total clones, but not in the count of
individual, distinct preys. c hAV interactors were confirmed by secondary assays. See
Table S1 for complete list of candidate interactors from the γ-SG yeast two-hybrid
screen.
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Figure 2.1. Archvillin binds γ-SG and dystrophin.
(A) Schematic of interacting domains in human archvillin for dystrophin and γ-SG. The
dystrophin preys all contain spectrin-like repeats 11-12; black bar indicates this predicted
binding region. The clones of archvillin preys interacting with γ-SG were identical,
encoding aa 2093-2214. Sequences of interest within human archvillin are indicated:
Blue-shading, muscle-specific differentially spliced sequences encoded by coding exons
3, 4, 5 [aa 277 – 669; yeast two-hybrid (Y2H) bait sequence] or coding exon 9 (aa 750781); red bars, predicted docking motifs for binding to ERK1/2 or other MAP kinases;
yellow bars, F-actin-binding regions; purple shading, nebulin-binding domain; green
shading, Y2H prey sequence recovered with the γ-SG bait. Schematics of dystrophin and
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γ-SG showing the locations of actin-binding domains 1 and 2 (ABD1, ABD2, orange),
numbered spectrin-like repeats 1 – 24, the cysteine-rich domain (CRD), and the carboxyterminus (COOH) of dystrophin, along with the transmembrane domain (TMD) and
extracellular domain (ECD) of γ-SG. The locations of potential ERK-binding sites were
predicted by The Eukaryotic Linear Motif (ELM) resource for Functional Sites in
Proteins using the default motif probability cutoff of 100 (http://elm.eu.org/), (Dinkel et
al., 2014). (B) Confirmation of γ-SG-archvillin interaction. Yeast containing either γSG/pGBKT7 or empty pGBKT7 plasmid were mated with yeast containing the archvillin
prey sequence (AV/pGADT7) identified in the yeast two-hybrid screen. White colonies
indicate the presence of both pGBKT7 and pGADT7 plasmids in diploid yeast. Blue
colonies indicate β-galactosidase gene activation from positive bait/prey interaction on
double dropout (DDO) and quadruple dropout (QDO) plates. Empty pGBKT7 and
AV/pGADT7 matings afforded colony growth on DDO plates, confirming that mated
yeast contained both plasmids, but not on QDO plates (negative control). (C) Co-IP of
archvillin and γ-SG. C57 and gsg-/- tibialis anterior (TA) muscle lysates were
immunoprecipitated with anti-γ-SG, and blots were probed with anti-archvillin and antiγ-SG. Lanes 1 and 2: Archvillin, γ-SG and tubulin in lysates (input). Archvillin coprecipitated with γ-SG in C57 muscle (lane 3), whereas no signal could be seen in gsg-/negative control IP (lane 4) or in negative control IPs without primary antibody (lanes 5
and 6). (D) Archvillin-specific sequence encoded by coding exons 3, 4, and 5 binds to
dystrophin spectrin repeats 10-12 in vitro. Immunoblots of recombinant His-tagged
DMD spectrin repeats (SR) 10-12 co-sedimented with the indicated GST fusion proteins.
Blots of bound and unbound fractions were probed with anti-His; Ponceau stain of bound
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fractions shows amounts of GST fusion proteins, as well as the bound His-DMD SR 1012 (aa 1361-1686) in Lane 3. Lane 1: His-DMD-10-12 input; Lane 2: GST (~26 kDa);
Lane 3: GST-AV-345 (doublet at 74 - 76 kDa) and His-DMD-10-12 (~45 kDa); and Lane
4: GST-AV-1-171 (~48 kDa).
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Archvillin levels depend on DGC integrity
Dystrophic muscle presents with an upregulation of membrane-associated
proteins involved in maintaining the cytoskeleton/ECM link and signaling; this includes
integrins, which are thought to function as a compensatory mechanism (Allikian et al.,
2004b; Barton, 2010; Hodges et al., 1997). We examined the expression of archvillin in
quadriceps, tibialis anterior (TA), extensor digitorum longus (EDL), soleus, diaphragm,
and heart muscles from C57, gsg-/-, δ-SG-null (dsg-/-), and mdx mice. Archvillin levels
were consistently elevated in gsg-/- and dsg-/- muscles, and were similar to C57 levels in
mdx muscles (Figure 2.2A). Western blot quantification and quantitative real-time PCR
showed that archvillin protein and mRNA were ~2.5-fold higher in gsg-/- quadriceps
muscle compared to C57 muscle, but were not significantly different in mdx muscle
(Figures 2.2B, 2.2C). Archvillin localization was first observed in hamster skeletal
muscle primarily along the sarcolemma, supporting the interaction with dystrophin (Oh et
al., 2003). To determine if archvillin localization was altered in dystrophic muscle, we
immunostained for archvillin in EDL muscles from C57, gsg-/-, and mdx mice. Similar to
previous observations, archvillin was localized in patches along the sarcolemma in C57
muscle. In gsg-/- muscle, archvillin was enriched at the sarcolemma and outlined nearly
the entire circumference of the muscle fibers. In mdx cross-sections, archvillin was
virtually undetectable along the sarcolemma (Figure 2.2D). Thus, localization of
archvillin to the sarcolemma depends upon the presence of dystrophin, but does not
require γ-SG. However, the compensatory increases of archvillin are apparent only in the
absence of the SG complex.
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Figure 2.2. Archvillin expression is altered in dystrophic muscle.
(A) Archvillin protein levels in quadriceps (Quad), tibialis anterior (TA), extensor
digitorum longus (EDL), soleus (Sol), diaphragm (Dia) and heart (Hrt) muscle of 12-14
week old C57/Bl6, gsg-/-, dsg-/-, and mdx mice. Increased archvillin is apparent in all
striated muscles from gsg-/- and dsg-/- mice. (B) Quantification of archvillin protein in
quadriceps confirms 2.7-4 fold increase of archvillin in gsg-/- and dsg-/- mouse muscles. *,
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P < 0.05; **, P < 0.01 vs. C57; †, P < 0.05 vs. mdx by one-way ANOVA with Bonferroni
post-hoc test, n = 3. (C) Quantitative RT-PCR for archvillin expression shows significant
upregulation in gsg-/- quadriceps muscles, as compared with C57 and mdx muscles. Bars
represent fold change; means ± SEM relative to C57. *, P < 0.05; **, P < 0.01 vs. C57; †, P
< 0.05 vs. mdx by one-way ANOVA with Bonferroni post-hoc test; n = 3-5. (D)
Immunostaining of EDL muscles shows that archvillin is localized primarily along the
sarcolemma in control C57 muscle, where it is present with increased intensity when γSG is absent in gsg-/- muscle. Archvillin localization is disrupted by the absence of
dystrophin in mdx muscle. Dotted line indicates γ-SG staining on an adjacent section.
Bars: 25µm. (E) Archvillin protein levels in quadriceps muscles from normal healthy
control, LGMD2C, LGMD2E, and DMD patient biopsies. Increased archvillin is
apparent in biopsies with primary sarcoglycan deficiency, whereas DMD patients with
primary dystrophin deficiency have reduced archvillin expression. All dystrophic
biopsies demonstrate elevated P-ERK activation vs. normal. Relative archvillin (AV)
values represent archvillin/tubulin relative to normal patients. Panels are from one
membrane with one lane removed for clarity. (F) Quantification of archvillin protein in
human quadriceps confirms ~4-fold increase of archvillin in LGMD2C patients. *, P <
0.05 vs. Normal; †, P < 0.05 vs. DMD by one-way ANOVA with Bonferroni post-hoc
test, n = 2-3; LGMD2E, n = 1 (not included in one-way ANOVA). See Table S2 for gene
mutations and age at time of biopsy of human patient biopsies.

	
  

41

To determine if archvillin levels were also altered in diseased human muscle, we
examined quadriceps muscle biopsies from LGMD2C, LGMD2E, and DMD patients
with primary deficiency in γ-SG, β-SG, and dystrophin, respectively. Immunoblotting
showed increased archvillin in LGMD2C biopsies, similar to observations in gsg-/muscle, whereas DMD muscle expressed slightly lower archvillin relative to normal
biopsies (Figures 2.2E, 2.2F). Therefore, in both mouse and human muscle samples,
archvillin levels increased in the absence of γ-SG, but were normal or reduced when
dystrophin was missing. We have previously shown that reintroduction of γ-SG in gsg-/muscle by recombinant adeno-associated virus (AAV) injection restores normal ERK1/2
signaling (Barton, 2010). To assess the dependence of archvillin on the presence of γ-SG,
we injected 3-week old gsg-/- mice with AAV expressing γ-SG and harvested tissue for
analysis 1-month post-injection. AAV injection restored γ-SG expression to C57 levels in
the injected limb and normalized archvillin expression levels (Figures 2.3A, 2.3B). Thus,
the level of archvillin in muscle appears inversely proportional to the presence of γ-SG.
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Figure 2.3. γ-SG restoration normalizes archvillin expression.
(A) Immunoblots of tibialis anterior (TA) muscles with (+) and without (-) injection of
adeno-associated virus (AAV) expressing human γ-SG show that archvillin expression
decreases with restoration of γ-SG expression (lane 6). (B) Western blot quantification
shows archvillin levels significantly decrease in gsg-/- TA muscles with γ-SG AAV
injection. Bars represent means ± SEM relative to C57 L. *, P < 0.05; **, P < 0.01 vs. C57
corresponding limb; †, P < 0.05 vs. gsg-/- R-; ‡, P < 0.01 vs. AAV gsg-/- L- by two-way
ANOVA and Bonferroni post-hoc test, n = 4-5.
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Archvillin association with P-ERK is stimulus-dependent
Mechanical perturbation evokes transient increases in P-ERK1/2 in skeletal
muscle (Martineau and Gardiner, 2001), and aberrant ERK signaling is common to many
mouse models of muscular dystrophies (Barton, 2006; Muchir et al., 2013; Wu et al.,
2014). Increased basal P-ERK is not only a phenotype of diseased murine muscle, but in
probing our biopsy samples from human patients, we found that P-ERK1/2 was also
elevated in all of the LGMD and DMD samples compared to biopsies from healthy
subjects (Figure 2.2E). Thus, identification of potential mediators of ERK signaling may
provide insight into disease mechanisms. Interestingly, the smooth muscle archvillin
isoform, which lacks the differentially spliced sequences by SVIL exons 3, 5, and 9, has
been shown to bind ERK in aortic tissue in a stimulus-dependent manner (Gangopadhyay
et al., 2009; Gangopadhyay et al., 2004). Candidate ERK docking sites exist in archvillin
(Figure 2.1A), raising the potential for a similar response to occur for this protein.
To determine if archvillin also associates with ERK, we subjected TA muscles to
a series of eccentric contractions (ECC) in situ during which the muscle was
simultaneously stimulated to contract and lengthened to induce maximal strain on the
membrane. Measurements of maximal isometric tetanic force showed that gsg-/- and mdx
muscle generated less force compared to C57 muscle (Figure 2.4A). However, following
ECC stimulation, the loss of force production in gsg-/- muscles was comparable to that in
C57 muscles, whereas mdx muscles displayed a significant drop in force generation
following ECCs (Figure 2.4B). This is consistent with studies performed on isolated
muscles from the gsg-/- mouse (Hack et al., 1999), and distinguishes the functional
phenotypes of gsg-/- and mdx muscles.
	
  

44

Figure 2.4. Archvillin associates with ERK1/2 in a stimulation- and sarcoglycandependent manner.
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Figure 2.4. Archvillin associates with ERK1/2 in a stimulation- and sarcoglycandependent manner.
(A) Dystrophic gsg-/- and mdx tibialis anterior (TA) muscles generate less force than C57
muscles when subjected to in situ isometric mechanical stimulation. *, P < 0.001 vs. C57
by one-way ANOVA with Bonferroni post-hoc test, n = 5-7. (B) Mice with primary γ-SG
deficiency do not show compromised force generating capacity following in situ
eccentric contraction mechanical injury, whereas mdx mice show a significant increase in
force drop. *, P < 0.001 vs. C57; †, P < 0.01 vs. gsg-/- by one-way ANOVA with
Bonferroni post-hoc test, n = 5-7. (C) Immunoprecipitation assay of TA muscles with (+)
and without (-) in situ eccentric contraction stimulation (Stim). Immunoprecipitation with
total ERK1/2 (T-ERK1/2) antibody shows that archvillin associates with ERK1/2 in
stimulated C57 muscle, but this association is lost in gsg-/- and mdx muscle. Without
stimulation, archvillin does not associate with ERK1/2 in any strain, indicating a
stimulation-dependent, sarcoglycan-dependent interaction. Immunoblotting for γ-SG
demonstrates that it does not associate tightly with ERK1/2. Tubulin serves as a loading
control for the inputs. (D) Immunoprecipitation with phospho-specific anti-P-ERK1/2
shows that archvillin associates with P-ERK1/2 only in stimulated C57 muscle. Results
were consistent from three independent experiments.
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Muscle lysates were immunoprecipitated with anti-ERK1/2 and probed for
archvillin, ERK1/2, and γ-SG. Archvillin associated with ERK1/2 in stimulated TA
muscles from C57 mice, but not in the non-stimulated contralateral control limb.
However, this association was eliminated in stimulated TA muscles from gsg-/- or mdx
mice, even though there was archvillin present in the lysates of all muscle samples
(Figure 2.4C). Interestingly, there was no direct interaction between ERK1/2 and γ-SG,
supporting that ERK1/2 associated with archvillin, but only when γ-SG was present. We
extended this evaluation to distinguish between archvillin association with
phosphorylated or non-phosphorylated ERK1/2, employing the same procedures, but
with an antibody specific to P-ERK1/2. The eccentric contractions produced a robust
increase in P-ERK1/2 in TAs from all three mouse lines. However, only stimulated C57
muscles displayed an association between P-ERK1/2 and archvillin, whereas stimulation
of dystrophic muscles failed to cause this interaction (Figure 2.4D). Taken together, PERK1/2 associates with archvillin in a stimulation- and γ-SG-dependent manner.

Nuclear P-ERK1/2 is elevated in dystrophic muscle
A central component of P-ERK1/2 activity is to phosphorylate transcription
factors in the nucleus, which then positively regulates target genes (Roux and Blenis,
2004b). Because we have previously established aberrant ERK1/2 signaling in dystrophic
muscles, we determined if this also altered the distribution of P-ERK1/2 between
cytosolic and nuclear fractions from C57, gsg-/- and mdx muscles. Fractioned lysates from
muscles subjected to eccentric contraction and from non-stimulated control muscles were
probed for P-ERK1/2. Eccentric contractions of TA muscles caused a dramatic increase
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in P-ERK1/2 that was most pronounced in the dystrophic muscles (Figure 2.5). Not only
was P-ERK1/2 elevated in the cytosolic fraction of muscles subjected to eccentric
contractions, there was enhanced localization of P-ERK1/2 in the nuclear fraction in both
gsg-/- and mdx muscles, suggesting that the aberrant signaling observed in whole muscle
lysates led to increased nuclear accumulation. Of note was the increase of lamin A/C in
the nuclear extracts of the dystrophic muscles. We performed additional probes with a
second nuclear marker (histone 3), which revealed that lamin A/C was elevated, as
opposed to an increase in nuclear content in these tissues, suggesting some compensatory
expression of lamin A/C associated with these dystrophies. In sum, the aberrant PERK1/2 signaling in gsg-/- and mdx muscle was associated with enhanced localization of
this signaling molecule in nuclear fractions.
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Figure 2.5. Nuclear P-ERK1/2 is elevated in dystrophic muscle following
stimulation.
Immunoblotting of cytosolic and nuclear fractions of tibialis anterior (TA) muscle with
(+) and without (-) in situ eccentric contraction stimulation (Stim). Stimulation led to
elevated P-ERK1/2 in both fractions, which was augmented in dystrophic muscles.
Nuclear accumulation of P-ERK1/2 was most pronounced in gsg-/- and mdx muscles with
stimulation. Lamin A/C was also elevated in nuclear fractions from dystrophic muscles.
Tubulin and histone 3 were used as loading controls and as cytosolic and nuclear
markers, respectively.
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ERK1/2 was not detectable in muscle cross-sections by immunofluorescence
Immunofluorescent staining of P-ERK1/2 and T-ERK1/2 was performed in 10um
TA muscle cross-sections from C57, gsg-/- and mdx mice with and without ECC
stimulation. Several conditions were tested in 4% formaldehyde and methanol/acetone
fixation, horse serum/BSA and 0.2% triton x-100 blocking solutions, and primary
antibody diltutions ranging from 1:5 to 1:500 applied either for 1 hour or overnight,
expanding upon the conditions recommended in the commercial specifications, as well as
those from papers detecting ERK1/2 in cell culture. However, none of these were
successful in detecting ERK1/2 in the sarcoplasm or the nucleus. Images from C57
muscle samples (Figure 2.6) are representative of all genotypes for ERK1/2.
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A

B

Figure 2.6. ERK1/2 is not detectable in cross-sections by immunofluorescence.
Immunostaining of 10µm cross-sections of C57 TA muscles with and without ECC
stimulation. Neither P-ERK1/2 (A) nor T-ERK1/2 (B) was detectable in the sarcoplasm
or the nucleus despite testing several staining conditions.
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2.3. Discussion
Growing evidence suggests that signaling defects associated with the loss of DGC
components contribute to the pathology of muscular dystrophy. In our previous work, γSG was shown to be a mediator of ERK1/2 signaling in response to mechanical
perturbation in skeletal muscle (Barton, 2010). However, the proteins involved in γ-SGmediated signaling are unknown, as the SG complex possesses no known enzymatic
activity. In the present study, we have identified the muscle-specific protein archvillin as
a γ-SG and dystrophin interacting protein through two independent screens and
biochemical assays. These results position archvillin as an intriguing component of the
mechanical signal transduction pathway associated with the DGC.
The proteins encoded by the Svil gene (supervillin, archvillin, smooth muscle
archvillin) are involved in many cellular processes, predominantly through their
association with the actin cytoskeleton. Archvillin has several associations with the
sarcolemma and cytoskeleton including binding to F-actin and non-muscle myosin (Chen
et al., 2003), localization with dystrophin at costameres (Oh et al., 2003), as well as
association with the C-terminus of nebulin (Lee et al., 2008). We show here that the Nterminal muscle-specific insert of archvillin binds to dystrophin, and also may interact
with the same domains of its ortholog utrophin. The dual interactions of archvillin with
both dystrophin and γ-SG suggest a strong association with the DGC that appears to be
independent of nebulin binding.
Given this association, we did not anticipate the alterations in archvillin levels and
localization observed in the absence of γ-SG and/or dystrophin. Because archvillin
interacts with nebulin and has multiple F-actin binding domains, one would predict that
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its localization near the membrane would be preserved in the absence of members of the
DGC. However, in the absence of dystrophin in mdx tissue, there was diminished
concentration of archvillin at the sarcolemma, suggesting that dystrophin is required for
archvillin to remain at the membrane. The fact that archvillin is de-localized, but not destabilized or degraded in mdx muscle, may be due to the many additional binding partners
for archvillin in the cell.
More surprising to us was the increased expression and accumulation of archvillin
at the sarcolemma in the absence of γ-SG. Given the upregulated γ-SG expression in gsg/-

muscle, it is possible that γ-SG positively regulates the degradation of archvillin.

However, archvillin is not upregulated in mdx muscle, suggesting that archvillin
expression may be mediated by another mechanism in the absence of dystrophin. Loss of
the SG complex also results in a compensatory increase in the integrin complex (Burkin
et al., 2001; Hodges et al., 1997), and so one possibility is that increased archvillin levels
are associated with integrin-associated proteins. While the related protein, supervillin,
regulates integrin function, there is no known direct binding of either protein to integrin,
though supervillin links to focal adhesions through binding to LIM domain proteins
TRIP6 and LPP (Takizawa et al., 2006). Ultimately, we cannot discount that the
increased archvillin in gsg-/- or in LGMD2C patients is correlated with integrin levels, but
even so, the stimulation and mechanically dependent ERK binding to archvillin is
completely eliminated in these muscles regardless of the 3-fold increase in the protein
levels. This implicates the SG complex in mediating archvillin-ERK association in
response to mechanical perturbation.
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Smooth muscle archvillin, a highly homologous isoform of archvillin, has been
implicated as an ERK scaffolding protein that binds ERK in a stimulus-dependent
manner (Gangopadhyay et al., 2009; Gangopadhyay et al., 2004; Li et al., 2009).
Archvillin also contains predicted ERK docking motifs, two of which are located within
the first muscle-specific insert (Dinkel et al., 2014), suggesting that it also has the
potential to bind ERK and mediate its activation in skeletal muscle, where there is
significant strain imposed on the sarcolemma. To investigate a potential archvillinERK1/2 interaction, we subjected muscles to an in situ eccentric contraction protocol,
which elicits dramatic P-ERK1/2 activation. Our results suggest that archvillin also
associates with ERK1/2, specifically with P-ERK1/2, in C57 muscle upon eccentric
contraction, through we cannot discern whether this interaction is direct or indirect
involving a yet to be identified intermediate. In either scenario, however, this association
is lost in gsg-/- and mdx muscle, indicating a γ-SG and dystrophin-dependent archvillin-PERK1/2 association. Complementary to this, we also observed increased nuclear PERK1/2 in stimulated gsg-/- and mdx muscles, presenting the possibility that loss of the
archvillin-ERK1/2 association in dystrophic muscle may contribute to the elevated
nuclear P-ERK1/2, and consequently, activation of downstream nuclear targets. From this
result, it is possible that in wild type muscle, archvillin may be acting as a P-ERK
sponge, and absence of its binding partners in dystrophic muscle disrupts their
interaction. Because there was also an increase in cytosolic P-ERK1/2 in stimulated
dystrophic muscle, we cannot distinguish between a model where there is a proportional
increase in nuclear translocation of P-ERK1/2, and the loss of the P-ERK1/2 interaction
is simply a parallel occurrence, or if indeed the loss of the archvillin-ERK1/2 association
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is contributing to aberrant P-ERK1/2 signaling. Ablation of archvillin would help to
evaluate the contribution of archvillin to P-ERK1/2 signaling and to the development of
muscle disease, but attempts at deleting the Svil gene have been unsuccessful. Targeting
the muscle specific insert may preserve the vital functions of supervillin in the rest of the
body, and afford examination of archvillin specific properties.
The potential for archvillin to play a role in mechanical signal transduction is high
given the known functions of this protein family. In addition to the ERK docking
properties of smooth muscle archvillin, nonmuscle supervillin controls stress-dependent
thrombus formation of platelets (Edelstein et al., 2012; Senetar et al., 2007), promotes
cell survival by suppressing p53 protein expression (Fang and Luna, 2013), and increases
the rapid recycling of integrins and other motile processes (Bhuwania et al., 2012;
Crowley et al., 2009; Fang et al., 2010; Smith et al., 2013; Takizawa et al., 2007). The
isoform switch from nonmuscle supervillin to archvillin occurs early in differentiation of
C2C12 murine skeletal myoblasts (Senetar et al., 2007), and suggests a muscle-specific
role for the protein, which is supported by its necessity to afford myotube formation of
these cells (Lee et al., 2008; Lim et al., 2007; Oh et al., 2003). While these properties
could be associated solely with actin cytoskeleton binding, the additional mechanically
sensitive ERK1/2 interaction with archvillin may contribute to its actions in muscle.
We were intrigued to find that the nuclear fractions from both dystrophic muscle
samples displayed increased lamin A/C. Because dystrophies exhibit heightened
degeneration and regeneration, as well as increased immune infiltration, the nuclear
content is elevated compared to healthy tissue (Evans et al., 2009). To control for this, we
loaded equal protein from each fraction and used histone 3 as a nuclear marker pointed to
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the specific elevation of lamin A/C. Lamin A/C gene (LMNA) mutations are one cause of
Emery-Dreifuss muscular dystrophy, and a mouse model for the LMNA H222P mutation
exhibits progressive dystrophic pathology and heightened ERK1/2 phosphorylation in
skeletal and cardiac muscle (Arimura et al., 2005; Muchir et al., 2013). Whether or not
the elevated lamin A/C in mdx and gsg-/- muscles is a compensatory measure to counter
nuclear accumulation of P-ERK1/2 is not known. Further, the potential interaction
between lamin A/C and archvillin identified in our yeast two-hybrid screen could
implicate archvillin-ERK1/2 binding at both the sarcolemma and nucleus. Ultimately,
these independent observations raise the potential for a common pathway – aberrant ERK
signaling – that contributes to a range of dystrophies. This is substantiated by the
upregulated P-ERK1/2 we observed in the LGMD and DMD human samples. Because
there is now evidence that pharmacologic ERK inhibition improves muscle function in
LMNA H222P EDMD mice (Muchir et al., 2013; Wu et al., 2014), application of this
strategy to other dystrophies is warranted.
A yeast two-hybrid screen using the intracellular domain of γ-SG as bait has been
performed previously (Blandin et al., 2013). Surprisingly, no preys emerged in common
between our two screens, suggesting that there may be many γ-SG interactors. Because,
to our knowledge, none of the prey hits from the previous screen have been pursued, the
interactions with archvillin characterized here may represent the first of many new
insights into processes involved in the dystrophic phenotype.
Based on our results, we provide a model in which archvillin sarcolemmal
expression and localization are dependent on both the SG complex and dystrophin, where
gsg-/- muscle has strongly upregulated archvillin levels concentrated at the sarcolemma
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(Figure 2.7). In the absence of both sarcoglycan and dystrophin binding partners in mdx
muscle, archvillin is no longer detected at the sarcolemma. The archvillin-P-ERK1/2
interaction is stimulus- and γ-SG-dependent, and we posit the possibility that the absence
of the SG complex or the entire DGC may contribute to the aberrant ERK signaling
observed in dystrophic muscle by an archvillin-mediated mechanism.
To our knowledge, this work in the first application of an in situ eccentric
contraction protocol on tibialis anterior muscles of γ-SG-null mice. Consistent with
previous ex vivo reports in EDL muscles, γ-SG deficiency does not cause contractioninduced injury, and is sufficient to compromise contractile force and cause muscle
degeneration. Further experiments will be required to determine the contribution of
archvillin to ERK signaling, and manipulation of ERK activity will provide insight into
its impact on pathology. If archvillin proves to have a substantial impact on ERK
signaling in muscle, it may be a viable target for muscle-specific manipulation of ERK
activation. Given the role of ERK signaling on cell survival and proliferation, targeting
archvillin may normalize the aberrant ERK activation and potential misregulation of its
targets in dystrophic muscle. In conclusion, we have implicated archvillin as a new player
in mechanical signal transduction in muscle, and that its localization and actions require
the presence of dystrophin and the sarcoglycans, respectively.
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Figure 2.7. Model of archvillin-γ-SG signaling. Archvillin sarcolemmal localization is
dependent on both the sarcoglycan complex and dystrophin. Muscle deficient in the
sarcoglycan complex alone in gsg-/- mice has strongly upregulated archvillin levels
concentrated at the sarcolemma. However, in the absence of both sarcoglycan and
dystrophin binding partners in mdx muscle, archvillin is no longer detected at the
sarcolemma. Archvillin exhibits stimulus- and γ-SG-dependent association with PERK1/2, where archvillin only associates with P-ERK in C57 muscle subjected to in situ
eccentric contraction mechanical stimulation, but this association is absent in gsg-/- and
mdx muscle with or without stimulation.
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Accession Number
Bait

γ-SG
aa 1-35

Interactors

Protein

Nucleotide

Number of Clones
Total

Individual

78 kDa glucose-regulated protein precursor (GRP78)

NP_005338.1

NM_005347.4

4

1

Coatomer subunit delta isoform 1 (COPD1)

NP_001646.2

NM_001655.4

4

1

Archvillin (SVIL)†

NP_003165.2

NM_003174.3

2

1

Coatomer subunit delta isoform 2 (COPD2)
DNA damage-regulated autophagy modulator protein 1
(DRAM1)

NP_001135753.1

NM_001142281.1

2

1

NP_060840.2

NM_018370.2

2

1

Na/K-transporting ATPase subunit beta-3 (ATP1B3)

NP_001670.1

NM_001679.2

2

1

60 kDa heat shock protein, mitochondrial (HSPD1)

NP_002147.2

NM_002156.4

1

1

Adenosylhomocysteinase isoform 1 (AHCY)

NP_000678.1

NM_000687.2

1

1

AP-2 complex subunit beta isoform b (AP2B1)

NP_001273.1

NM_001282.2

1

1

Beta-sarcoglycan (SGCB)

NP_000223.1

NM_000232.3

1

1

COP9 signalosome complex subunit 5 (COPS5)

NP_006828.2

NM_006837.2

1

1

Cubilin precursor (CUBN)

NP_001072.2

NM_001081.3

1

1

DnaJ homolog subfamily B member 4 (DNAJB4)

NP_008965.2

NM_007034.3

1

1

Dynein heavy chain 14, axonemal isoform 1 (DNAH14)

NP_001364.1

NM_001373.1

1

1

Glutamate--cysteine ligase regulatory subunit (GCLM)
Sodium/potassium-transporting ATPase subunit beta-1
(ATP1B1)

NP_002052.1

NM_002061.2

1

1

NP_001668.1

NM_001677.3

1

1

Neurexin-1-beta isoform alpha1 precursor (NRXN1)

NP_004792.1

NM_004801.4

1

1

PDZ and LIM domain protein 2 isoform 2 (PDLIM2)

NP_067643.3

NM_021630.5

1

1

Phospholipid scramblase 1 (PLSCR1)

NP_066928.1

NM_021105.2

1

1

Probable G-protein coupled receptor 115 precursor (GPR115)
Propionyl-CoA carboxylase alpha chain, mitochondrial isoform
a precursor (PCCA)
Propionyl-CoA carboxylase alpha chain, mitochondrial isoform
b (PCCA)

NP_722580.3

NM_153838.3

1

1

NP_000273.2

NM_000282.3

1

1

NP_001121164.1

NM_001127692.2

1

1

Protein transport protein Sec31A isoform 1 (SEC31A)

NP_055748.2

NM_014933.3

1

1

Protein transport protein Sec31A isoform 2 (SEC31A)

NP_057295.2

NM_016211.3

1

1

Protein transport protein Sec31A isoform 3 (SEC31A)

NP_001070676.1

NM_001077208.2

1

1

Protein transport protein Sec31A isoform 5 (SEC31A)

NP_001177978.1

NM_001191049.1

1

1

Sperm-associated antigen 17 (SPAG17)

NP_996879.1

NM_206996.2

1

1

Splicing factor 3B subunit 1 isoform 1 (SF3B1)

NP_036565.2

NM_012433.2

1

1

Splicing factor 3B subunit 3 (SF3B3)

NP_036558.3

NM_012426.4

1

1

Thioredoxin-like protein 1 (TXNL1)
Translation initiation factor IF-2, mitochondrial precursor
(MTIF2)

NP_004777.1

NM_004786.2

1

1

NP_002444.2

NM_002453.2

1

1

Uncharacterized protein C17orf46 (SPATA32)

NP_689556.2

NM_152343.2

1

1

WD repeat-containing protein 5B (WDR5B)

NP_061942.2

NM_019069.3

1

1

WD repeat-containing protein 61 (WDR61)

NP_079510.1

NM_025234.1

1

1

Supplemental Table 2.1. Complete list of candidate interactors from γ-SG yeast twohybrid assay
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CHAPTER 3: Absence of γ-sarcoglycan Alters the Response of p70S6 Kinase to
Passive Stretch in Murine Skeletal Muscle

This chapter is adapted from and excerpt of:
Catherine Moorwood, Anastassios Philippou, Janelle M. Spinazzola, Benjamin Keyser,
Edward J. Macarak, Elisabeth R. Barton. 2014. Absence of γ-sarcoglycan alters the
response of p70S6 kinase to mechanical perturbation in murine skeletal muscle.
Skeletal Muscle 4:13.
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3.1 Summary
Deficiency in the sarcoglycan (SG) complex alone is sufficient to cause muscular
dystrophy including severe myofiber degeneration, yet without causing susceptibility to
contractile damage. This suggests that disease occurs not by structural deficits, but
through aberrant signaling, namely, disruption of normal mechanotransduction signaling
through the SG complex. In this chapter, we extended our previous studies on
mechanosensitive, γ-sarcoglycan (γ-SG) dependent ERK1/2 phosphorylation to
determine whether additional pathways are altered with the loss of γ-SG. We examined
mechanotransduction in the presence and absence of γ-SG, where signaling protein
phosphorylation was determined by immunoblotting of lysates from C2C12 myotubes
and isolated muscles from C57Bl/6 (C57) and γ-SG-null (gsg-/-) mice with and without
cyclic passive stretch. C2C12 myotube stretch caused a robust increase in P-p70SK, but
decreased P-FAK and P-ERK2. Neither Akt nor ERK1 were responsive to passive
stretch. In isolated muscles, Akt, S6RP, and p70S6K activation increased with stretch in
both C57 and gsg-/- isolated muscles. Dependence on mTOR was determined by
stretching isolated muscles in the presence or absence of rapamycin, which blocked all of
p70S6K activation in stretched C57 muscles, and reduced downstream S6RP
phosphorylation. However, even though rapamycin treatment decreased p70S6K
activation in stretched gsg-/- muscles, S6RP phosphorylation remained elevated. Our
results suggest that p70S6K is an important component of γ-SG-dependent
mechanotransduction in skeletal muscle, where loss of γ-SG uncouples the response of
p70S6K to stretch and implies that γ-SG is important for inactivation of this pathway.
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Overall, we assert that altered load-sensing mechanisms exist in muscular dystrophies
where the sarcoglycans are absent.
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3.2 Introduction
The dystrophin glycoprotein complex (DGC) is found at the sarcolemma of
skeletal, cardiac, and smooth muscle cells, where it physically links the extracellular
matrix (ECM) with the intracellular cytoskeleton, providing structural support (Lapidos
et al., 2004). Mutations in DGC components cause different types of muscular dystrophy;
for example, mutations in dystrophin cause Duchenne muscular dystrophy (DMD), while
mutations in α-, β-, γ-, or δ-sarcoglycan (SG) cause limb girdle muscular dystrophy
(LGMD) (Durbeej and Campbell, 2002; Engel and Franzini-Armstrong, 2004). When
dystrophin is mutated in DMD or in the mdx mouse model of DMD, the entire DGC is
substantially reduced at the sarcolemma. In contrast, when any one of the SGs is mutated,
in LGMD or any of the SG knock-out mice, the other three SGs are either absent or
reduced at the sarcolemma, but the rest of the DGC remains, including the link formed by
dystrophin and dystroglycan between the cytoskeleton and ECM and (Blake et al., 2002;
Durbeej and Campbell, 2002). Unlike the skeletal muscles of the mdx mouse, muscles of
the γ-SG-null (gsg-/-) mouse display no mechanical fragility, at least until 4 months of
age, as shown by a minimal loss of force-generating capacity following a series of
eccentric contractions (ECCs) (Hack et al., 1999; Petrof et al., 1993). In spite of this, the
gsg-/- mouse exhibits a severe dystrophic phenotype on histological examination, with
extensive myofiber degeneration and regeneration, fibrosis, and disruption of
sarcolemmal integrity, similar to the mdx mouse (Hack et al., 1998). The lack of
mechanical fragility suggests that aberrant signaling may contribute to the muscle
degeneration seen in the gsg-/- mouse. Indeed, our previous studies demonstrated that
localization of the SG complex to the sarcolemma and phosphorylation of the tyrosine 6
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residue of γ-SG are essential for normal signaling by extracellular signal-regulated
kinases 1 and 2 (ERK1/2), in response to ECCs (Barton, 2006; Barton, 2010). Based
upon these data, we have asserted that the SG complex acts as a mechanosensor in
skeletal muscle because of its position within the DGC, the modifications that occur to γSG with mechanical perturbation, and the necessity of the complex for normal signaling.
One pathway of interest involves p70S6K, which is canonically activated in
response to mitogens via the phosphoinositide 3-kinase (PI3K) pathway (Fenton and
Gout, 2011) and is known to respond to mechanical load (Hornberger et al., 2004).
Activation of p70S6K involves a hierarchical series of phosphorylation events, beginning
with phosphorylation of multiple sites in the C-terminal autoinhibitory domain, followed
by mammalian target of rapamycin (mTOR)-dependent phosphorylation of sites in the
linker region, which allows for full activation of the kinase via phosphorylation of
threonine 229 (T229) in the catalytic domain by phosphoinositide-dependent kinase 1
(PDK1) (Dufner and Thomas, 1999). Although phosphorylation of T229 is required for
p70S6K activation, phosphorylation of T389 in the linker region has been found to
correlate most closely with in vivo activity (Pearson et al., 1995), and can be used as a
measure of kinase activation. p70S6K has a multitude of downstream targets, with roles
in protein synthesis, growth, proliferation, survival, and more (Fenton and Gout, 2011),
including S6 ribosomal protein (S6RP), which closely correlates with protein translation
rates (Nielsen et al., 1982).
In this chapter, we examined ERK1/2, Akt, focal adhesion kinase (FAK), and
p70S6K responses to passive stretch in C57 and gsg-/- skeletal muscle to further elucidate
the importance of the SG complex for mechanotransduction. We used a passive
	
  

64

stretching protocol to isolate the effects of externally applied tension in the absence of
active contraction, in order to examine the downstream signaling in more detail. The
p70S6K response to stretch in isolated extensor digitorum longus (EDL) muscles was
differentially regulated in the absence of γ-SG. Specifically, experiments in isolated
muscles suggest that γ-SG is required for inactivation of p70S6K. The findings increase
our understanding of the contribution of aberrant load-sensing to the pathology of
muscular dystrophies where the SG complex is deficient.
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3.3 Results

p70S6K, but not ERK1/2 or Akt, responds to passive stretch in vitro
Studies using whole muscles from animal models of the dystrophies are made
more complex by the presence of multiple cell types, as well as pathological processes
such as fibrosis. Therefore, we initially investigated mechanotransduction signaling in
passively stretched C2C12 myotubes. We found that passive stretching in vitro did not
alter phosphorylation of ERK1 or Akt, and that ERK2 and FAK phosphorylation
decreased following stretch (Figure 3.1A,C-F, H-I). However, we found an increase in
p70S6K phosphorylation at T389, which reflects activity, in response to passive
stretching of C2C12 myotubes (Figure 3.1B,G). Therefore, this in vitro model reflected
some, but not all, stretch responses observed in muscle in vivo (Hornberger et al., 2005;
Martineau and Gardiner, 2001), and highlighted p70S6K as a pathway of interest. The
lack of Akt phosphorylation suggests that p70S6K phosphorylation occurred through an
Akt-independent pathway, while the lack of FAK phosphorylation supports an integrinindependent mechanism.
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Figure 3.1. p70S6K responds to stretch in C2C12 cells.
C2C12 myotubes were cultured on silicone membranes and subjected to passive
stretching for 30 min. (A-D) Representative immunoblots for P-ERK1/2, T-ERK1/2, Pp70S6K (T389 site), tubulin, P-Akt, T-Akt, P-FAK, and T-FAK in non-stretched (NS)
and stretched (S) C2C12 cells. (E-I) Quantification of phosphorylation levels. P-ERK1
and 2 were normalized to T-ERK1 and 2, respectively, P-p70S6K was normalized to
tubulin, P-Akt was normalized to T-Akt, and P-FAK was normalized to T-FAK. n = 5-6
wells of C2C12 cells per group. Bars represent mean ± standard error. * Significantly
different from non-stretched myotubes by unpaired Student’s t-test. NS, non-stretched; S,
stretched.
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Passive stretch is sufficient to induce tyrosine phosphorylation of γ -SG
Previous studies have shown that the SG complex is sensitive to mechanical
stimulation. Each of the sarcoglycans undergoes adhesion-dependent phosphorylation in
cell culture studies (Yoshida et al., 1998). In addition, whole muscles also exhibit posttranslational modification of intracellular tyrosine(s) following eccentric contractions
(Barton, 2006). However, it was not clear if the strain imposed by passive stretch alone
could generate the same response in muscles. A passive stretching protocol comprised of
a 15% strain, 20 times per min, for 30 min in high-glucose DMEM was sufficient to
cause increased γ-SG phosphorylation in the EDL, as is the case for eccentric contraction
of the EDL (Figure 3.2A (Barton, 2006)).
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Figure 3.2. γ-SG is tyrosine phosphorylated in response to passive stretch in isolated
C57 EDL muscle.
EDL muscles from C57 mice were maintained in oxygenated high glucose DMEM and
subjected to passive stretching. (A) Immunoblot of γ-SG following immunoprecipitation
with anti-P-Tyr or lysate only, showing γ-SG phosphorylation in response to 30 min of
stretch. Protein loading: 200µg IP lanes, 50µg Input lanes. NS, non-stretched; S,
stretched.
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Stretch response of p70S6K T389, but not S6RP, is rapamycin-sensitive in gsg-/muscles
Because mTOR is a key mediator of p70S6K activation, we examined the effect
of the mTOR inhibitor rapamycin on stretch responses in isolated C57 and gsg-/- muscles.
EDL muscles were subjected to cyclic stretch as described above. Unlike in C2C12 cells,
P-Akt showed a trend to increase on stretching, which was statistically significant in gsg/-

muscles. As anticipated, P-Akt was unaffected by rapamycin (Figure 3.3A,B).

Rapamycin treatment completely blocked the increase in p70S6K T389 phosphorylation
after passive stretch of C57 muscles, consistent with previous studies (Dufner and
Thomas, 1999; Hornberger et al., 2004). In gsg-/- muscles, rapamycin abrogated most
p70S6K T389 phosphorylation, but residual phosphorylation remained in stretched
muscles (Figure 3.3A,C). T421/S424 showed a trend to increase in response to stretch in
both C57 and gsg-/- muscles. Surprisingly, rapamycin blunted the p70S6K T421/S424
stretch response in C57 muscles, which is inconsistent with previous studies (Hornberger
et al., 2004). However, the T421/S424 response to stretch persisted in gsg-/- muscles in
the presence of rapamycin (Figure 3.3A,D). S6RP phosphorylation increased in response
to stretch in both C57 and gsg-/- muscles. Interestingly, while rapamycin blocked stretchinduced phosphorylation of S6RP in C57 muscles, phosphorylation in response to stretch
was preserved in gsg-/- muscles (Figure 3.3A,E). Taken together, these results suggest
either that the level of active p70S6K remaining in gsg-/- muscles is sufficient to
phosphorylate S6RP regardless of rapamycin or that an alternate pathway bypasses
p70S6K to phosphorylate S6RP in muscles lacking γ-SG.
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Figure 3.3 Stretch response of p70S6K T389, but not S6RP, is rapamycin-sensitive
in gsg-/- muscles.
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Figure 3.3. Stretch response of p70S6K T389, but not S6RP, is rapamycin-sensitive
in gsg-/- muscles.
EDL muscles from C57 and gsg-/- mice were maintained in oxygenated high glucose
DMEM supplemented with or without rapamycin and subjected to passive stretching. (A)
Immunoblots of P-Akt, T-Akt, P-p70S6K (T389 and T421/S424 sites), P-S6RP, and
tubulin. Left panels DMEM alone; right panels DMEM + rapamycin. (B-E)
Quantification of P-Akt (B), P-p70S6K T389 (C), P-p70S6K T421/S424 (D), and PS6RP (E). Legend in B applies to all graphs. P-Akt was normalized to T-Akt; all other
proteins were normalized to tubulin. Bars represent mean ± standard error. *P < 0.05 vs.
respective NS; †P < 0.05 vs. respective control without rapamycin by two-way ANOVA
with Tukey’s multiple comparisons test; n = 2-3 muscles per genotype and condition. NS,
non-stretched; S, stretched.
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3.4. Discussion
Skeletal muscle has the ability to adapt to changes in workload. Almost all muscle
properties can be modulated, such as muscle fiber size, contractile properties and
metabolism. Changes in patterns of gene expression as well as shifts in the balance
between protein synthesis and degradation are required to mediate the response.
Identification of major pathways that directly regulate gene expression and protein
synthesis/degradation demonstrate that multiple inputs (mechanical, chemical, and
metabolic) can converge on final common pathways for muscle growth and adaptation
(Glass, 2003). However, sorting out the contribution of the wide variety of inputs on
muscle adaptation has been more difficult. In our previous work, we used an eccentric
contraction protocol to investigate the dependence of ERK1/2 mechano-sensing on
phosphorylation of γ-SG. However, this protocol alters multiple factors, including
externally applied tension and internally generated tension, which potentially have effects
on mechanosensitive signaling pathways. In this study, we used a passive stretching
protocol to isolate the effects of externally applied tension in the absence of active
contraction, in order to examine the downstream signaling in more detail.
Passive stretching protocols can be performed in both cell cultures and whole
muscle preparations, and the reductionist approach of utilizing cultures can eliminate
some of the physiological complexities associated with intact or isolated muscles. As
such, our initial experiments using C2C12 cells served in identifying p70S6K as being
activated in response to stretch, in contrast to the lack of response by ERK1/2, Akt, or
FAK. Using isolated muscles from C57 and gsg-/- mice to investigate γ-SG-dependent
mechanotransduction pathways, we observed a modest increase of P-p70S6K in gsg-/	
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muscles at rest, and a prolonged activation of p70S6K following stretch. These results
support a role for γ-SG in mechanical signal transduction, where the loss of this protein
leads to inappropriate activation and/or deactivation. Given the dependence of our
findings on the experimental platform utilized, verification of the results in an in situ
muscle model should be included in future directions.
A potential explanation for our in vivo results is that γ-SG is required for
dephosphorylation and deactivation of p70S6K. There is considerable evidence that
p70S6K is directly dephosphorylated by protein phosphatase 2A (PP2A), independently
of mTOR (Cho et al., 2006; Hahn et al., 2010; Peterson et al., 1999; Petritsch et al.,
2000). The phosphatase PHLPP has also been shown to target p70S6K (Liu et al., 2011),
and γ-SG may mediate the activation of these phosphatases in response to sustained
mechanical stimulation. Alternatively, γ-SG may regulate pathways that deactivate
p70S6K indirectly. For example, the phosphatase SHP-2 can cause mTOR-dependent
dephosphorylation of p70S6K (Ketroussi et al., 2011; Zito et al., 2007). Further studies
will be required to define the inactivation pathway disrupted by γ-SG loss.
In this study, we sought to identify mechanosensitive signaling that is attributable
to the SG complex rather than other processes occurring during mechanical perturbation.
By using passive stretch models, we eliminated the contribution of active contraction or
SR calcium fluxes. However, this does not eliminate the effects of extracellular Ca2+
fluxes through mechanically sensitive channels, and it has been shown previously that
passive stretch causes greater Ca2+ influx into myotubes lacking members of the SG
complex (Sampaolesi et al., 2001). This raises the possibility that the mechanical signal
transduction pathways we evaluated previously may be modulated not only by the SG
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complex, but also by additional channels in the sarcolemma. To address this, additional
work not presented in this dissertation was performed in this study examining the
contribution of calcium to the elevated p70S6K and ERK1/2 activity found in muscles.
By maintaining isolated muscles in calcium-free of tetracaine-supplemented Ringer’s
solution, it was found that the elevation of P-ERK1/2 in the absence of γ-SG was
dependent on both internal and external sources of calcium. In contrast, the difference in
basal P-p70S6K between C57 and gsg-/- muscles was not calcium dependent (data not
shown). This suggests that while ERK1/2 activation may lie downstream of the calcium
misregulation that occurs in SG-deficient muscle, changes in p70S6K activation may be a
more direct consequence of the absence of the SG complex. This is of considerable
interest given that γ-SG has been shown to be important for mechanotransduction, but the
downstream signaling pathways are uncharacterized (Barton, 2006; Barton, 2010).
The pattern of differential p70S6K phosphorylation in response to stretch in gsg-/muscles was similar both for phosphorylation of T389, which correlates with kinase
activity, and for T421/S424, two of the four phosphorylation sites in the autoinhibitory
domain. Phosphorylation of T389 is mTOR-dependent, while phosphorylation of the
autoinhibitory domain is carried out by proline-directed kinases. Furthermore, it is
thought that phosphorylation of the autoinhibitory domain is necessary for
phosphorylation of T389 (Dufner and Thomas, 1999). Therefore, the correlation between
phosphorylation of T421/S424 and T389 in our isolated muscle model suggests that
phosphorylation of the autoinhibitory domain was the rate-limiting step for p70S6K
activation, which is of interest given that the autoinhibitory domain may be targeted by
ERK1/ 2 (Mukhopadhyay et al., 1992). Therefore, a future hypothesis to test is that
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differential p70S6K activation is a downstream consequence of differential ERK1/2
activation in gsg-/- muscle.
Our experiments with rapamycin showed that, for both C57 and gsg-/- muscles,
phosphorylation of p70S6K at T389 is mTOR-dependent, consistent with previous
studies (Dufner and Thomas, 1999; Hornberger et al., 2004). The T421/S424
autoinhibitory domain sites were phosphorylated in response to stretch in both C57 and
gsg-/- muscles. However, in the presence of rapamycin, this response was not present.
This is surprising given that the T421/S424 sites are not thought to be targeted by mTOR.
Previous studies have shown these sites to be rapamycin-insensitive (Hornberger et al.,
2004), but recent evidence suggests a modest mTOR dependence (Axelrod et al., 2014).
In gsg-/- muscles, rapamycin had no effect on T421/S424 phosphorylation. Further
experiments are needed to fully understand the role of mTOR on phosphorylation of the
p70S6K autoinhibitory domain in C57 and gsg-/- skeletal muscle. Interestingly, the stretch
induced phosphorylation of S6RP was rapamycin sensitive in C57 muscles, but not in
gsg-/- muscles. This suggests that an alternative pathway can bring about S6RP
phosphorylation in gsg-/- muscles when p70S6K is not activated. One possibility is that
S6RP is phosphorylated by p90 ribosomal S6 kinase, which is activated by ERK. This is
consistent with the increase in basal ERK1/2 in gsg-/- muscle, and the over-response of
ERK2 with mechanical stimulation by eccentric contraction (Barton, 2006).
We did not observe a strong Akt response to passive stretch or any difference
between C57 and gsg-/-, implying that mTOR and/or p70S6K were being activated
through Akt-independent pathways. This is consistent with previous studies showing that
Akt does not respond to mechanical stimulation in skeletal muscle, and that p70S6K
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phosphorylation in response to stretch is independent of PI3K (Hornberger and Chien,
2006). We also did not see increased phosphorylation of FAK in response to passive
stretch in C2C12 cells. Although integrins can participate in mechanotransduction, it
appears that our cyclic passive stretch protocols did not cause integrin activation (data not
shown). Further studies will be needed to elucidate the details of crosstalk between SGdependent and integrin-dependent signaling pathways.
Based on our findings, we position γ-SG as a mechanosensor important for
transient ERK1/2 activation during active contractions, as well as for modulation of
p70S6K activation during passive stretch. Because passive stretch does not appear to
increase P-FAK or P-Akt, γ-SG is likely to regulate p70S6K through other pathways.
These may include regulation of ERK1/2, which can promote p70S6K activation
indirectly via mTOR or directly by phosphorylation of the autoinhibitory domain, and/or
phosphatases such as PP2A that dephosphorylate p70S6K. Loss of γSG uncouples the
response to stretch, which may contribute to muscle pathology.
The stability of the SG complex is directly affected in several LGMDs and in
DMD, and growing evidence suggests that inappropriate load sensing contributes to the
pathology of these diseases. The first step in therapeutic development is identifying and
understanding the target, but little is currently known about the role of the SG complex in
load sensing. Therefore, understanding the functions that are disrupted and the pathways
that are involved in mechanotransduction involving the SG complex will help in the
design of therapies for LGMDs and DMD. While restoration of a completely normal SG
complex either through gene correction or protein replacement would also normalize
mechanical signal transduction, this may not be possible for all mutations responsible for
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DMD and LGMD. It is known that localization of the SG complex is not the sole
criterion for appropriate signaling (Barton, 2010), and downstream pathways may emerge
as more feasible therapeutic targets.
We do not know whether the enhanced basal and stretch-responsive activation of
p70S6K in gsg-/- muscle contributes to pathology or compensates for it. Likewise, it is not
clear whether inhibition of p70S6K would have a beneficial or a detrimental effect in
dystrophic muscle. Muscle-specific gene targeting of mTORC1 components induces
myopathy (Bentzinger et al., 2008; Risson et al., 2009), and overexpression of integrin α7
can improve the dystrophic phenotype through increased survival signaling via p70S6K
(Boppart et al., 2011), suggesting that p70S6K inhibition would not be advantageous.
However, treatment of mdx mice with the mTOR inhibitor rapamycin improves the
dystrophic phenotype (Eghtesad et al., 2012). It is also interesting to note that p70S6K is
inhibited by glucocorticoids, which are used in the treatment of DMD and LGMD (Shah
et al., 2000). Based on these observations, it is clear that there is a narrow window of
effective p70S6K activation and that any intervention to alter its activity would require
considerable fine-tuning.
We have identified p70S6K as part of a novel SG-dependent mechanosensitive
signaling pathway in skeletal muscle. Our results suggest that γ-SG is required for the
inactivation of p70S6K following its activation in response to mechanical stimulation. In
addition to increasing our understanding of the normal function of the SG complex, these
results begin to provide mechanistic insight into how mechanical signaling is disrupted
and altered in the absence of γ-SG. As we learn more about the mechanisms by which
signaling defects may contribute to dystrophic pathology, there is potential to identify
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more refined targets that could be beneficial to patients either in isolation or in
combination with other therapeutic approaches.

	
  

79

CHAPTER 4: PILOT STUDY
EFFECTS OF SHORT-TERM TREATMENT WITH ERK1/2 INHIBITOR
SCH772984 IN MOUSE MUSCLE

This chapter describes pilot experiments to determine the utility of the ERK1/2 inhibitor
SCH772984 in mouse muscle subjected to mechanical stimulation
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4.1 Summary
Growing evidence suggests that disrupted signaling pathways associated with the
loss of the dystrophin-glycoprotein complex contribute to muscle disease. Heightened PERK1/2 activity in skeletal muscle is a feature of several muscular dystrophies. In this
chapter, we assess the utility of a newly developed ERK1/2 specific inhibitor
SCH772984 in C57 and gsg-/- mice for future use in determining the effect of reducing
ERK1/2 activity to prevent or ameliorate dystrophic pathology. Five days of treatment
with 12.5mg/kg SCH772984 in 6-7 week old mice decreased P-ERK1/2 in mouse heart,
diaphragm, and liver, but not in tibialis anterior muscle with or without in situ eccentric
contraction. Treatment with SCH772984 did not affect force generation or contractioninduced injury in either strain. C57 and gsg-/- mice treated with SCH772984 lost
significant of body weight compared to their respective untreated controls, which gained
weight. These results position SCH772984 as a potentially effective ERK1/2 inhibitor in
select tissues, and address potential pitfalls for future investigation.
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4.2 Introduction
Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways
involved in the regulation of normal cell proliferation, survival and differentiation (Roux
and Blenis, 2004a). The extracellular signal-regulated kinase (ERK) MAPK pathway is
of particular interest given that hyperactivation of this pathway is a feature of muscle
diseases such as Duchenne Muscular Dystrophy (DMD) and Limb-Girdle Muscular
Dystrophies (LGMD) (Barton, 2006). These diseases are caused by mutation and loss of
members of the dystrophin glycoprotein complex (DGC) such as γ-sarcoglycan (γ-SG),
which has been shown to be a mediator of ERK1/2 signaling (Barton, 2006; Barton,
2010). Growing evidence suggests that in addition to mechanical perturbations, disrupted
signaling pathways associated with the loss of DGC components contribute to disease
pathology (Barton, 2010; Hack et al., 1999). However, ERK1/2 misregulation has not yet
been directly linked to manifestation of dystrophic pathology in DMD and LGMDs.
ERK1/2 are downstream components of an evolutionarily conserved signaling
module that is activated by the Raf serine/threonine kinases. Raf activates the
MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, which then activate
ERK1/2 (McCubrey et al., 2007). In skeletal muscle, ERK1/2 activation is positively
correlated to tension (Martineau and Gardiner, 2001). Chronic activation of this signaling
pathway has been implicated in the development and perpetuation of a number of
different pathologies, such as diabetes, cachexia, and cancer (McCubrey et al., 2012).
However, ERK1/2 is also stimulated by exercise, promoting improvements in fuel
homeostasis, and can prevent skeletal muscle atrophy (Salto et al., 2014; Shi et al., 2009).
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Thus, appropriate tuning of this signaling pathway seems to be critical for maintaining
healthy muscle.
Most research targeting ERK1/2 inhibition as a therapeutic agent has been in
cancer (Figure 4.1). Several Ras inhibitors have reached clinical testing, but have been
unsuccessful due to off-target effects, reducing interest in Ras as a therapeutic target
(Rusconi et al., 2012). However, MEK is considered an attractive drug target since
ERK1/2 are the only known targets (Kolch, 2000; Wei et al., 2011). Although the first
two MEK inhibitors, PD98059 and U0126, were highly specific (Davies et al., 2000),
their pharmacological characteristics rendered them unsuitable for clinical development
(Dudley et al., 1995). Use of the first clinically tested MEK inhibitor, Cl-1040, was
discontinued due to lack of reduced ERK phophorylation in a phase II study (Rinehart et
al., 2004), though there have been promising phase I clinical trial results with a second
generation MEK inhibitor PD-0325901 (Haura et al., 2010).

Figure 4.1. Inhibitors of the MAPK/ERK signaling pathway
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Recently, there have been promising results in the use of MEK inhibitors to treat
muscular dystrophy. Autosomal Emery-Dreifuss muscular dystrophy is caused by
mutations in the lamin A/C gene (LMNA) encoding A-type nuclear lamins, resulting in
muscle weakness, cardiomyopathy and heightened ERK1/2 activity. Treatment of mice
with the MEK inhibitor selumetinib ameliorated skeletal muscle histopathology, reduced
centrally nucleated fibers, and improved muscle function as assessed by in vivo grip
strength testing (Muchir et al., 2013). Given these results, the potential use of an ERK1/2
specific inhibitor to treat SG-deficient muscular dystrophies, which also present with
heightened ERK1/2 activity, is an attractive prospect.
The small molecule SCH772984 is a selective inhibitor of ERK1/2 that has been
shown to effectively inhibit MAPK signaling and cell proliferation in MEK-inhibitor
resistant tumor cells. In vivo, tumors in nude mice showed diminished ERK1/2 activity
and suspended growth following 14 days of twice-daily i.p. injection with 12.5-50mg/kg
SCH772984 (Morris et al., 2013). Therefore, a similar strategy may reduce the ERK1/2
activity in γ-SG-deficient dystrophic muscle. In this chapter, we assess the utility of
SCH772984 in γ-SG-null (gsg-/-) mice for future investigation as a potential treatment to
prevent or ameliorate dystrophic pathology associated with sarcoglycan deficiency. The
goal was to determine if SCH772984 treatment was effective in lowering P-ERK1/2
without harmful side effects.
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4.3 Results

SCH772984 inhibits ERK1/2 in C57 and gsg-/- heart and liver
Mechanical stimulation evokes ERK1/2 activation in skeletal muscle (Martineau
and Gardiner, 2001), and dystrophic muscle displays aberrant ERK1/2 signaling both at
rest and with stimulation (Barton, 2006; Barton, 2010). We examined the
phosphorylation of ERK1/2 in tibialis anterior (TA), heart, and liver lysates from C57
and γ-SG-null (gsg-/-) mice with and without SCH772984 ERK1/2 inhibitor treatment. PERK1/2 was elevated in gsg-/- TA muscle at rest compared to muscles from C57 mice, but
SCH772984 did not reduce ERK1/2 at rest or following eccentric contraction (ECC)
stimulation (Figure 4.1A,B,F). Even though TA muscles did not appear to respond to
SCH772984, the treatment effectively inhibited ERK1/2 phosphorylation in heart,
diaphragm, and liver lysates from both C57 and gsg-/- mice (Figure 4.2A,C-E,G-I). These
results support that the 12.5mg/kg dose of SCH772984 is sufficient to modulate PERK1/2 in multiple tissues, but suggest that skeletal muscles may be unresponsive to the
actions of the inhibitor, or require a different dosing regimen.
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Figure 4.2. SCH772984 inhibits ERK1/2 in murine heart, diaphragm, and liver, but
not in TA muscle with or without ECC.
6-7 week old C57 and gsg-/- mice were treated for 5 consecutive days with 12.5mg/kg
SCH772984 delivered by i.p. injection. (A) Immunoblotting of tissue lysates from mice
with (+) and without (-) SCH772984 treatment, and with (+) and without (-) in situ
eccentric contraction stimulation (Stim). (B,F) SCH772984 treatment did not inhibit
ERK1/2 activation in tibialis anterior (TA) muscle +/- stimulation. (C-E,G-I) SCH772984
treatment decreased ERK1/2 activation in heart, diaphragm, and liver lysates. TA bar
graphs (B,F) are represented on a log2 scale. n = 1-2.
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SCH772984 does not compromise TA force-generating capacity
To determine the effect of SCH772984 on muscle function, we subjected TA muscles of
mice with and without treatment to a series of eccentric contractions in situ.
Measurements of maximal isometric tetanic force showed that gsg-/- muscles generated
less force compared to C57 muscle as observed previously (Spinazzola et al., 2015), and
that SCH772984 did not affect force in either strain. Following ECC stimulation, the loss
of force production in control gsg-/- muscles was comparable to that of control and treated
C57 muscle (Figure 4.3). Interestingly, SCH772984 treatment seemed to increase percent
force drop in gsg-/- mice, though this was not statistically significant. Thus, the inhibitor
does not appear to negatively affect muscle force production.
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Figure 4.3. Treatment with SCH772984 does not affect TA response to mechanical
stimulation. (A) Dystrophic gsg-/- TA muscles generate less force than C57 muscles
when subjected to in situ isometric mechanical stimulation. SCH772984 treatment does
not affect force generation in either strain. (B) gsg-/- mice with and without SCH772984
treatment do not show compromised force generating capacity following in situ eccentric
contraction mechanical injury. *, P < 0.05 vs. C57 by two-way ANOVA with Bonferroni
post-hoc test, n = 3. Bars represent means ± SEM.
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Mice treated with SCH772984 lose body weight
To determine the effect of SCH772984 treatment on overall wellness, we tracked
body weight before and throughout treatment. Both C57 and gsg-/- mice treated with
SCH772984 showed significant difference in weight compared to their respective
untreated controls (Figure 4.4). Treated mice lost an average of 5.5% of their initial body
weight compared to untreated controls, which gained an average of 2.6% of initial body
weight. This suggests that this drug may compromise animal health and not be usable for
long-term treatment.
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Figure 4.4. Short-term treatment with SCH772984 causes mice to lose body weight.
Both C57 and gsg-/- mice treated with 5 days of 12.5mg/kg SCH772984 (black) lost
weight compared to untreated controls (white), which gained weight. *, P < 0.05 vs.
strain-matched control by two-way ANOVA with Bonferroni post-hoc test, n = 3.
Symbols represent means ± SEM.
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4.4 Discussion
Growing evidence suggests that disrupted signaling pathways associated with the
loss of DGC components contribute to muscle disease. In our previous work, γ-SG was
shown to be a mediator of ERK1/2 signaling, which is heightened in several forms of
muscular dystrophy (Barton, 2006; Barton, 2010). In this chapter, we assessed the utility
of a novel ERK1/2 specific inhibitor SCH772984 in C57 and gsg-/- mice for future
investigation as a strategy to prevent or ameliorate dystrophic pathology. Our results
showed that SCH772984 can inhibit ERK1/2 in a subset of tissues at the dose tested, but
also revealed potential pitfalls to consider with extended treatment.
The reason for lack of effect of SCH772984 in inhibiting ERK1/2 in TA muscle
as opposed to in the heart, diaphragm, and liver is unclear. In accord with this, it was not
unexpected that SCH772984 did not alter maximal tetanic force generated in gsg-/following stimulation. Given that the circulation to limb muscles is at a minimum in
resting mice, it is possible that the biodistribution of the inhibitor was low to these muscle
groups. Altering the treatment regimen may help to improve the exposure to inhibitor, or
incorporation of increased cage activity to the study would increase circulation to the
limbs and provide better biodistribution. However, given its effect in the heart, it would
be of interest to see if SCH772984 treatment yielded any cardiac improvements given
that gsg-/-, dsg-/- and mdx mice develop cardiomyopathy (Coral-Vazquez et al., 1999;
Hack et al., 2000; Quinlan et al., 2004). Long-term treatment with the MEK1/2 inhibitor
PD98059 has been found to prevent cardiomyopathy, including left ventricular endsystolic dilation, increase ejection fraction, and decrease myocardial fibrosis in the
H222P mouse model of autosomal Emery-Dreifuss muscular dystrophy (Wu et al., 2014).
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In addition, long-term SCH772984 treatment on the diaphragm would also be of interest,
as it is the most affected muscle in mdx mice and its failure is often the cause of death in
DMD patients.
The significant loss of body weight in treated animals with just five days of oncedaily 12.5mg/kg SCH772984 raises concern about potential long-term and high-dose
testing. Treated mice lost an average of 5.5% of their initial body weight compared to
untreated controls, which gained an average of 2.6% of initial body weight (Figure 5.3).
This was unexpected given that no weight loss or lethality was reported in nude mice
given twice-daily doses up to 50mg/kg for two weeks (Morris et al., 2013). Future
investigation with SCH772984 should include body weight monitoring to assess
secondary effects exasperated with long-term or high-dose treatment.
The ERK MAPK pathway is critical in mediating cell proliferation,
differentiation, and survival. ERK1/2 has several cytoplasmic and nuclear targets
including P90RSK and transcription factors Elk-1 and myc that are phosphorylated in
response to mechanical perturbation (Yu et al., 2001). If SCH772984 did prove to be a
beneficial in ameliorating or preventing pathology, the next steps would include
investigation of these downstream ERK1/2 targets to determine if they are differentially
regulated in normal versus dystrophic muscle. Given findings of aberrant p70S6K
activation in γ-SG-deficient muscle subjected to passive stretch (Moorwood et al., 2014),
it is likely that multiple pathways, in addition to ERK1/2, are disregulated.
With growing evidence of the importance of signaling cascades mediated by the
DGC in muscle, and aberrations in the ERK cascade identified in several forms of
muscular dystrophy, targeting this pathway may be a viable component of a multifaceted
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therapeutic strategy. Despite variable success with small molecules inhibitors such as
SCH772984 in the clinical setting, they have been invaluable academic research tools for
dissecting the ERK pathway. Even if SCH772984 itself cannot be utilized as a clinical
treatment, it may reveal insight into the contribution of disrupted ERK signaling in the
development of dystrophic pathology.
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CHAPTER 5: Conclusions and Future Directions

Conclusions
The DGC is a key player in muscle adaptation to load. Mutations in genes
encoding the DGC cause several forms of muscular dystrophy, emphasizing its
importance in maintaining healthy, functional muscle. However, the mechanisms by
which each of these components contributes to the development of disease pathology is
unclear. With the discovery of dystrophin as the protein associated with Duchenne
Muscular Dystrophy nearly thirty years ago, early observations suggested that dystrophy
was a consequence of a mechanical deficit. However, increasing evidence has revealed
that signaling pathways disrupted with mutation of components of the DGC contribute to
the development of dystrophic pathology. In the present work, we investigated the
contribution of γ-SG to signaling in normal and γ-SG-deficient muscle. We reaffirm the
position of γ-SG as a mechanosensor and expand on its role in regulating signaling in
skeletal muscle. Further, we introduce the protein archvillin as a mechano-sensitive
protein associated with the DGC.
Yeast two-hybrid screens identified archvillin as a γ-SG- and dystrophininteracting protein. We verified that archvillin associates with γ-SG in murine skeletal
muscle, and that muscle-specific region of archvillin binds to the rod domain of
dystrophin. We confirmed with immunostaining that archvillin is localized at the
sarcolemma, and that it is delocalized from the sarcolemma in the absence of dystrophin.
Moreover, we show that archvillin expression is dependent on γ-SG expression. Muscle
lacking γ-SG displayed increased archvillin expression concentrated at the sarcolemma,
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and reintroduction of γ-SG in gsg-/- muscle by AAV injection reduced archvillin
expression to wild type levels. To test our hypothesis that archvillin, like its closely
related isoform smooth muscle archvillin, associates with ERK1/2, we
immunoprecipitated muscle lysates with and without in situ ECC mechanical stimulation
with anti-ERK1/2 and probed for archvillin. Archvillin associated with P-ERK1/2 in C57
stimulated muscle, but not on gsg-/- or mdx muscle. These findings led us to propose a
model in which γ-SG and dystrophin mediate archvillin expression, localization, and
association with P-ERK1/2 in skeletal muscle.
In addition, we extended our previous studies on mechanosensitive, γ-SG
dependent ERK1/2 phosphorylation to determine whether additional pathways are altered
with the loss of γ-SG. We examined mechanotransduction in lysates from C2C12
myotubes and isolated muscles from C57 gsg-/- mice with and without cyclic passive
stretch. C2C12 myotube stretch caused a robust increase in P-p70SK, but decreased PFAK and P-ERK2, and neither Akt nor ERK1 were stretch responsive. In isolated
muscles, Akt, S6RP, and p70S6K activation increased with stretch in both C57 and gsg-/isolated muscles. Treatment with the mTOR inhibitor, rapamycin, blocked all of p70S6K
activation in stretched C57 muscles, and reduced downstream S6RP phosphorylation.
However, even though rapamycin treatment decreased p70S6K activation in stretched
gsg-/- muscles, S6RP phosphorylation remained elevated, suggesting that γ-SG may be
important for inactivation of this pathway and that loss of γ-SG uncouples the response of
p70S6K to stretch. These data suggest that there are differentially altered load-sensing
mechanisms in muscular dystrophies where the sarcoglycans are absent. Overall, this
work provides further evidence that γ-SG impacts mechanical signal transduction in
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skeletal muscle, and present archvillin as a new DGC-interacting protein and further
evidence for a role of γ-SG as a mechanosensor in skeletal muscle. In this chapter, I
discuss the significance of these findings and provide insight into directions for future
research.

Remaining Questions and Future Directions
The role of archvillin in signaling
We have shown that archvillin associates with P-ERK1/2 in a γ-SG- and stimulusdependent manner. Previous studies on the isoform smooth muscle archvillin showed that
it serves as a scaffold and impacts ERK1/2 phosphorylation in aortic tissue
(Gangopadhyay et al., 2009; Gangopadhyay et al., 2004), posing the question if archvillin
plays a similar role in skeletal muscle. Knockdown of smooth muscle archvillin was
achieved by delivery of antisense oligonucleotides by a four-day organ culture “chemical
loading procedure” (Gangopadhyay et al., 2009). While this long-term technique is not a
feasible strategy in skeletal muscle, knockdown of archvillin in skeletal muscle would be
of considerable interest. Attempts to generate a knockout mouse by our collaborators
were unsuccessful, but other methods to knock down archvillin in muscle could include
delivery of siRNA or antisense oligos by alternative methods. For example, gene
silencing in limb muscles of old and young mice has been reported in a developing
technique involving siRNA delivery via intravascular injection with and without
electropulsation (Golzio et al., 2005; Hagstrom et al., 2004).
Using this or alternative methods, knockdown of archvillin in wild type mice
would allow us to determine the contribution of archvillin alone to skeletal muscle
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signaling defects and/or pathology. Knockdown of archvillin in gsg-/- muscle would also
determine whether γ-SG mediates ERK1/2 signaling through its association with
archvillin, providing evidence of this potential mechanism of regulation posed in Chapter
2. If archvillin does prove to be a primary mediator of ERK1/2 signaling, its manipulation
could be a strategy by which to influence ERK1/2 signaling in a skeletal muscle-specific
manner. Smooth muscle archvillin lacks multiple muscle insert sequences encoded by
exons 3 and 5, as well as the second muscle-specific archvillin insert encoded by exon 9
(Gangopadhyay et al., 2004; Oh et al., 2003). By targeting these archvillin exclusive
sequences, one could direct deletion strategies to archvillin specifically, and avoid
interference of smooth muscle archvillin or supervillin. In addition to differences in
muscle insert sequences, archvillin and smooth muscle archvillin also have different
predicted ERK1/2 binding sites. Two of the three predicted ERK1/2 binding sites of
archvillin are within the first muscle-specific region (aa 277 – 669) (Dinkel et al., 2014),
whereas both smooth muscle archvillin sites, P219 and P774, are outside of the musclespecific region. This may influence how ERK1/2 associates with each isoform and alter
the downstream effects.

Association of archvillin with the other sarcoglycans
The work in Chapter 2 used the intracellular domain of γ-SG as bait in a yeast
two-hybrid screen to identify archvillin as a binding partner. Given the homology of βSG, and especially δ-SG, to γ-SG, this poses the question of whether archvillin might also
associate with them. Similar immunoprecipitation experiments to those described in
Chapter 2 could be performed using antibodies against the other SGs and immunoblotting
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with anti-archvillin. These could be followed up with yeast two-hybrid experiments to
reaffirm archvillin and also identify other potential binding partners. The secondary loss
or reduction of the other complex members from loss of one subunit suggests that the
SGs may work cooperatively, but each individual subunit’s function versus as a complex
is not known. Given the importance of each SG in the formation of the complex, it is
possible that they work in a coordinated manner to mediate interactions with intracellular
binding partners and associated signaling pathways. Evidence of either shared or
individual binding partners or functions would be of interest, and perhaps shed light onto
the mechanisms underlying the variability in disease progression and pathology amongst
LGMD types 2C-F.

Impact of γ -SG phosphorylation
Phosphorylation is a versatile post-translational modification, as it is readily
added and removed from substrates by kinases and phosphatases, respectively, allowing
for a dynamic regulation of protein function in response to an ever changing cellular
environment. In addition to acting as a molecular mark whose presence or absence can be
recognized by other proteins, the negative charge inherent to the phosphate moiety can be
utilized to alter protein structure or interaction/affinity with other proteins.

Does γ-SG tyrosine 6 mediate its association with archvillin?
Previous work in our lab demonstrated that γ-SG is tyrosine phosphorylated in
response to mechanical stimulation and that the γ-SG tyrosine 6 affects ERK1/2
signaling, where expression of a WTgsg construct, but not a mutant Y6A construct in
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gsg-/- muscle was able to restore normal ERK1/2 signaling (Barton, 2010). Having
identified archvillin as γ-SG-associated protein that also binds P-ERK1/2 in a stimulusdependent manner in Chapter 2, whether γ-SG Y6 phosphorylation impacts binding
dynamics is of interest. By similarly reintroducing either normal γ-SG or mutant Y6A γSG by AAV expression, we could determine whether this residue is important for γ-SGarchvillin association. Further, we could determine if γ-SG Y6 phosphorylation impacts
archvillin association with P-ERK1/2 in muscle subjected to in situ ECC. This would
demonstrate that Y6 phosphorylation not only affects P-ERK1/2 signaling, but also
provide evidence of a γ-SG-mediated ERK1/2 signaling mechanism through archvillin. If
γ-SG Y6 does impact the γ-SG-archvillin and archvillin-P-ERK1/2 associations, it would
suggest that binding γ-SG may impart some conformational change that affects its ability
to bind P-ERK1/2.

Does phosphorylation of the other Y residues of g-SG affect (ERK1/2) signaling?
Since the initial experiments investiating the significance of γ-SG Y6
phosphorylation on ERK1/2 signaling, updated algorithms have also identified other
tyrosine residues of the γ-SG intracellular domain as predicted phosphorylation sites.
Therefore, it would be of interest to assess the significance of each of these residues by
expressing γ-SG constructs with individual and combinatorial mutations in gsg-/- muscle,
and assessing their influence on ERK1/2 activation with and without mechanical
stimulation. This would tell us which specific tyrosine residues are actually
phosphorylated in response to active contraction, and which are important for mediating
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ERK1/2 signaling and for γ-SG interaction with archvillin. In addition to γ-SG, the
intracellular regions of the α- and β-SG subunits of the SG complex also have poential
phosphorylated tyrosine residues (Yoshida et al., 1998). Therefore, it would be
interesting to see if tyrosine phosphorylation of the other SGs imparts effects on ERK1/2
signaling.

Consequences of aberrant ERK1/2 signaling in skeletal muscle
We have demonstrated here and previously the aberrant ERK1/2 signaling in
murine skeletal muscle lacking γ-SG in response to both passive and active stretch in ex
vivo and in vitro models. Given the significance of ERK1/2 signaling in mediating cell
proliferation and survival pathways, we pose the question of whether its misregulation is
sufficient to cause dystrophic pathology, and if inhibition may prevent or ameliorate
pathology. Inhibition of ERK1/2 signaling with the small molecule MEK1/2 inhibitor,
selumetinib, has been found to prevent pathology in a mouse model of Emery-Dreifuss
muscular dystrophy with primary lamin A/C gene mutation, which also exhibits
heightened ERK1/2 activity (Muchir 2013, Wu 2014). Using a similar approach, we
performed pilot experiments utililizing a new ERK1/2-specific inhibitor, SCH772984
(see Chapter 5). Short-term intra-periotoneal injection of the drug at 12.5 mg/kg was
effective in decreasing basal ERK1/2 activation in both the heart and liver. This is of
interest because cardiomyopathy is a feature of LGMD in both humans and animal
models lacking the SGs. Going forward, it will be important to address the long-term
delivery potential of this drug and perhaps other ERK1/2 inhibitors.
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Amelioration of pathology by inhibition of another aberrant signaling pathoway
has recently been reported in γ-SG-deficient mice. Ex vivo ECC stimulation elicits
increased accumulation of nuclear phosphorylated SMAD2/3 in gsg-/- mice EDL muscles.
By introducing a heterozygous mutation of SMAD4 into gsg-/- mice to reduce but not
ablate SMAD4, Goldstein et al. showed that these mice had improved body mass, cardiac
function and improved tetanic force (Goldstein et al., 2014). Given these positive effects
by normalizing an aberrant signaling pathway in the gsg-/- mouse, we believe the
preventative and ameliorative capacity of SCH772984 or another MEK or ERK inhibitor
is worthy of further investigation.
In addition to histopathological and functional consequences of aberrant ERK1/2
signaling, it would also be of interest to look at expression differences of ERK1/2 targets
in dystrophic muscles. In chapter 2, we reported an increase in nuclear P-ERK1/2 in gsg-/and mdx muscle, indicating the potential for differentially regulated transcription factors.
Therefore, an assessment of genes differentially expressed in gsg-/- and mdx muscle, with
and without mechanical stimulation, focused on ERK1/2 mediated targets would be of
interest. Studies of differentially expressed genes using microarray data has been
performed comparing biopsies from unaffected control, DMD, and LGMD2A/B patients
(Eisenberg et al., 2007; Haslett et al., 2002), but not in muscle with primary SG mutation.

p70S6K activation with active stretch
In Chapters 2 and 3, we demonstrated differential activation of signaling
pathways including ERK1/2 in response to passive and active stretch models. Therefore,
the analysis of signaling pathways induced by different mechanical stimuli is important to
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fully understand their function. Expanding our investigation of mTOR effector p70S6K
activation in dystrophic muscle to include its response to our in situ ECC protocol is of
interest given its role in skeletal muscle in mediating muscle protein synthesis. Parallel or
synergic pathways can be activated through different stimuli; therefore, like ERK1/2,
p70S6K may also be differentially activated with active stretch in dystrophic muscle.
Similarly, we also posit whether γ-SG Y6 tyrosine phosphorylation impacts
p70S6K activation as it does ERK1/2. This could be analyzed by AAV-mediated
reintroduction of either WTgsg or Y6Agsg in gsg-/- mice muscle with and without ECC.
If p70S6K activation does depend on γ-SG phosphorylation, this raises the possibility that
differential p70S6K activation is a downstream consequence of differential ERK1/2
activation in gsg-/- muscle. Contrary to this, recent work by others has shown that stretchinduced activation of mTOR and p70S6K at T389 is independent of ERK1/2 (Carriere et
al., 2011; You et al., 2014). Whether γ-SG is modulating ERK1/2 and p70S6K in parallel
or sequentially is important for understanding if one or both pathways leads to pathology,
and ultimately can aid in designing therapeutic strategies that target signaling.

Concluding remarks
Under healthy conditions, skeletal muscle is a highly plastic tissue, capable of
adapting to countless adverse conditions and impositions. However, in several muscular
dystrophies in which the stability of the SG complex compromised, inappropriate load
sensing appears to contribute significantly to disease pathology. The first step in
therapeutic development is identifying and understanding the target, but little is currently
known about the role of the SG complex in load sensing. Therefore, understanding the
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functions that are disrupted and the pathways that are involved in mechanotransduction
involving the SG complex will help in the design of therapies for LGMDs and DMD,
perhaps by revealing more feasible therapeutic targets. To this end, the findings described
in this dissertation begin to provide mechanistic insight into how mechanical signaling is
disrupted and altered in the absence of γ-SG. In addition to increasing our understanding
of the normal function of the SG complex, there is potential to provide more refined
targets that could be beneficial to patients either in isolation or in combination with other
therapeutic approaches.
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CHAPTER 6: Materials and Methods

Yeast two-hybrid assays
Two independent yeast two-hybrid assays were performed to identify binding
partners for the intracellular domain of γ-SG, and binding partners for the muscle-specific
insert of archvillin. The Matchmaker 3 system (Clontech, Mountain View, CA) was used
to perform the γ-SG yeast two-hybrid assay. The bait plasmid was generated by cloning
the cDNA sequence corresponding to the intracellular domain of human γ-SG
(NG_008759) (aa 1-35) into the pGBKT7 bait vector containing the DNA binding
domain (BD) of Gal4. The bait plasmid was electroporated into AH109 yeast. The
normalized human cDNA library prey, fused to the activation domain (AD) of Gal4, was
pre-transformed in AH109 yeast. The mated yeast were screened on trp-, leu-, his-, ade-,
x-alpha-Gal+ media plates (dropout media for positive selection of bait and prey plasmids
and their interaction), and colonies that grew and were blue were considered hits. All
appropriate control tests were performed as described in the assay kit. Prey fragments
from all positive hits were amplified by PCR, sequenced, and identified using the
GenBank database (NCBI). A confirmation of binding assay for the archvillin prey was
performed as described in the Matchmaker 3 system. In short, AH109 yeast containing
either empty pGBKT7 plasmid or the γ-SG/pGBKT7 bait constructs were mated with
Y187 yeast containing the archvillin/pGADT7 plasmid prey identified from the original
yeast two-hybrid screen. The mated yeast were screened on either double drop out (DDO)
trp-, leu-, x-alpha-Gal+ plates or quadruple dropout (QDO) trp-, leu-, his-, ade-, x-alphaGal+ media plates.
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Archvillin yeast two-hybrid screening was performed by Hybrigenics Services,
S.A.S., Paris, France (http://www.hybrigenics-services.com). The sequence from the
differentially spliced coding exons 3, 4, and 5, which encodes a large N-terminal insert
(amino acids 276 – 669) in human supervillin isoform 2 (archvillin, NP_068506) and in
supervillin isoform 4 (AGE81989.1) was generated by PCR (Fang and Luna, 2013; Oh et
al., 2003). This PCR-amplified sequence was cloned into pB27, a derivative of
pBTM116 (Vojtek and Hollenberg, 1995), as a C-terminal fusion to LexA (N-LexASVIL-C) and into pB66, a derivative of pAS2ΔΔ (Fromont-Racine et al., 1997), as a Cterminal fusion to the Gal4 DNA-binding domain (N-Gal4-SVIL-C). The constructs
were verified by sequencing and used as baits for screening a random-primed Human
Adult and Fetal Skeletal Muscle cDNA library in pP6, a derivative of pGADGH (Bartel
et al., 1993). The LexA bait construct was used to screen 61 million clones (6-fold
coverage of the library), using a mating approach with YHGX13 (matα) and L40ΔGal4
(mata) yeast strains, as previously described (Fromont-Racine et al., 1997) yielding a
total of 17 positive colonies. The Gal4 construct and the same mating approach were
used to screen 50 million clones (5-fold library coverage) with HGX13 (matα) and
CG1945 (mata) yeast strains, yielding a total of 42 positive colonies. The prey fragments
of the positive clones were confirmed for interaction, amplified by PCR, sequenced, and
identified using the GenBank database (NCBI).

Generation of His-DMD-10-12
An intein-tagged plasmid encoding dystrophin spectrin repeats (aa 1361-1686;
pTYB1-DMD-10-12), a kind gift from Dr. Elisabeth Le Rumeur (Université de Rennes),
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was used as template for PCR using the following primers: sense: 5'GAATTCATGAGGCAAAAGTTGCTTGAACAGAGCATC; antisense: 5'CTCGAGACTGGTCAAAAGTTTCCATGTGTTTCTGGTA. The resulting fragment
was cloned into the pET30a+ vector using the EcoRI and XhoI restriction sites as
described previously (Takizawa et al., 2006). The vector was verified by sequencing.

Recombinant protein purification
GST fusion proteins and His-DMD-10-12 were purified from Rosetta 2 pLysS
(DE3) cells (EMD-Millipore Biosciences, Billerica, MA), grown and extracted as
described previously (Smith et al., 2010). Briefly, cells were induced with 0.2 mM IPTG
at 30oC for 18 h and collected by centrifugation before resuspension and extraction. The
GST proteins (Smith et al., 2010) and His-tagged DMD 10-12 (Takizawa et al., 2003)
was retrieved, as described. His-tagged DMD 10-12 beads were washed five times with
10 ml of wash buffer B (10 mM phosphate buffer, pH 7.5, 60 mM NaCl, 2% glycerol,
0.01% DTT, and 20 mM imidazole) (Takizawa et al., 2003). Three 1-ml fractions were
eluted using wash buffer B containing 250 mM imidazole. All purified proteins were
analyzed by SDS-PAGE.

GST pulldown experiments and His immunoblot analysis
Immediately prior to use, the purified His-DMD-10-12 solution in wash buffer B
was modified to contain 90 mM NaCl, 2 mM DTT, 10 mg/ml BSA, and 1% Tween-20
and clarified by centrifugation at 15,000 x g for 15 minutes. After the His-DMD-10-12
supernatant was transferred to a fresh tube, 100 µl aliquots were mixed with 200 µl of
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GST or GST fusion proteins, and incubated for 2 h at 4oC with rotation. Aliquots of
glutathione-Sepharose 4B (50 µl slurry volume; GE Healthcare Bio-Sciences,
Piscataway, NJ) were washed three times with wash buffer before addition of the
GST/His protein mixtures, then incubated at 4oC with agitation for 1.5 hours. The
Sepharose beads were collected by centrifugation, and the supernatants were saved as
unbound fractions. Beads were then washed five times with 500 µl of 0.5x TBST (83.5
mM NaCl, 5 mM Tris, 0.025% Tween-20, pH 7.5); at the second wash, the bead slurry
was moved to a fresh tube. Bound fractions were eluted with 100 µl of 10 mM
glutathione in wash buffer B. All samples were solubilized in Laemmli Sample Buffer
(Laemmli, 1970), resolved on 12% SDS-PAGE gels, and transferred to 0.45 µm
nitrocellulose (Whatman GmBH, Dassel, Germany). Immunoblots were probed using
rabbit polyclonal anti-His (Cell Signaling, Beverly, MA) and HRP conjugated goat antirabbit (Jackson ImmunoResearch, West Grove, PA), developed using SuperSignal
WestFemto ECL (Thermo Scientific; Rockford, IL) and imaged on a BioRad Gel Doc
with Image Lab 4.1 software (BioRad, Hercules, CA). The experiment was repeated
twice with comparable results.

Immunohistochemistry
10 µm frozen cross-sections from the midbelly of EDL muscles were fixed for 10
minutes in 4% formaldehyde and washed three times with PBS, followed by staining
using the mouse-on-mouse (M.O.M) staining kit (Vector Laboratories, Burlingame, CA).
Sections were blocked for 1 hour at room temperature in blocking buffer plus 2% horse
serum and 2% BSA in phosphate buffered saline (PBS), then incubated overnight at 4°C
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in M.O.M. diluent with rabbit polyclonal anti-archvillin (Sigma Life Sciences, St. Louis,
MO, A1355) and anti-dystrophin (Vector Laboratories; VP-D505) or anti-γ-SG (Vector
Laboratories VP-G803), all at 1:10 dilution or anti-laminin (Thermo Scientific RB-082A) at 1:500. Secondary antibodies were applied at 1:500 (Life Technologies, Grand
Island, NY; A11034, S32354, S32356), and slides were mounted using Vectashield with
DAPI (Vector). Images were acquired at 400x on a Leica DMR microscope and Leica
DFC300 CCD camera, using Improvision OpenLab software (Perkin Elmer, Waltham,
MA).

Immunoprecipitation
Immunoprecipitation experiments were carried out using the Pierce Classic IP kit
(Thermo Scientific). Muscle lysates containing 100 µg or 200 µg total protein were
immunoprecipitated with anti-P-ERK1/2 (Thr202/Tyr204) (Cell Signaling; #9101 1:100),
anti-ERK1/2 (Cell Signaling; #9107 1:100), anti-γ-SG (Vector Laboratories; VP-G803
1:20), or anti-P-Tyr (Cell Signaling; #9411 1:50) overnight at 4oC with end-over-end
mixing. The immune complex was eluted with non-reducing sample buffer and boiled at
100oC for 5 minutes before being applied to a SDS-PAGE gel and immunoblotted as
described below.

Immunoblotting
Snap frozen tissues were ground using a mortar and pestle over dry ice. Both snap
frozen tissues and C2C12 myotubes were lysed in RIPA buffer RIPA buffer (50 mM
HEPES pH7.5, 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, 15 mM p-nitrophenyl
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phosphate disodium hexahydral, 1% NP-40, 0.1% SDS, 1% deoxycholate, 0.025%
sodium azide) with protease and phosphatase inhibitor cocktails added (Sigma). Lysates
were incubated on ice for 1 hour, vortexing half way through, centrifuged at 14K rpm for
30 minutes at 4oC and the supernatants retained. Protein concentration was measured
using a Bradford method protein assay kit (Bio-Rad). Lysates were separated by SDSPAGE on Tris-HCl polyacrylamide gels (Bio-Rad) and transferred to PVDF membranes.
Membranes were blocked in 5% milk and 2% BSA in TTBS, then probed with antibodies
to the following: anti-archvillin (Oh et al., 2003) 1:500, anti-P-ERK1/2 (Thr202/Tyr204)
(Cell Signaling; #9101 1:1,000), anti-total-ERK1/2 (Cell Signaling; #9107 1:1,000), antiγ-SG (Vector Laboratories; VP-G803, 1:300), anti-β-SG (Vector Laboratories; VP-B206
1:500), anti-δ-SG (Vector Laboratories; VP-D501 1:50), anti-histone 3 (Cell Signaling;
#9715 1:2,000), anti-tubulin (Sigma; T5168 1:20,000), anti-lamin A/C (Cell Signaling;
#2032 1:500), anti-GAPDH (Santa Cruz; sc-32233 1:5,000), phospho (P)-p70S6K (T389)
(Cell Signaling #9234 1:250), P-p70S6K (T421/S424) (Cell Signaling; #9204 1:1,000),
P-S6RP (Ser235/236) (Cell Signaling; #2211 1:2,000), P-Akt (Ser473) (Cell Signaling;
#9271 1:300), T-Akt (Cell Signaling; #2920 1:2,000), P-FAK (Tyr397) (Millipore; 051140, 1:500), T-FAK (Millipore; 06-543, 1:1,000). Membranes were then incubated with
HRP-conjugated secondary antibodies (Cell Signaling; #7074, #7076 1:2,000), and
visualized using ECL Plus reagent (Thermo Scientific) and autoradiography film
(BioExpress, Kaysville, UT).
For human samples, 25 pooled, 10 µm frozen sections of quadriceps biopsies
from LGMD2 patients, DMD patients and healthy male controls were lysed in RIPA
buffer, and 5% of the lysate was used for immunoblotting, as described above. Samples
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were obtained from the Wellstone Muscular Dystrophy Tissue and Cell Repository at the
University of Iowa Carver College of Medicine (Iowa City, IA). LGMD patients were
between 9 and 17 years, DMD patients between 5 and 8 years, and controls between 8
and 13 years at the time of biopsy (Supplemental Table II).

Quantitative RT-PCR
Total RNA was isolated from frozen quadriceps muscles using TRIzol (Life
Technologies). Equal amounts of total RNA from each sample were subjected to singlestrand reverse transcription (Applied Biosystems, Foster City, CA-now part of Life
Technologies). The resultant cDNA was utilized for quantitative real-time PCR with
primers specific for archvillin exon 4: sense - 5' AAAGAGGAGAGTGCTCGCAG 3';
antisense: - 5' GCTGGTGACCCTATCAAAGGT 3', using the Applied Biosystems 7300
Real-Time PCR System and reagents (Power SYBR Green PCR Master Mix, Life
Technologies). All samples were loaded in duplicate in 96-well plates. Expression of 18S
was used to control for cDNA content.

Animals
All experiments were approved by the University of Pennsylvania Institutional
Animal Care and Use Committee. C57Bl/6 (C57), γ-SG-null (gsg-/-), δ-SG-null (dsg-/-),
and mdx mice were used. Three-week old mice were used for viral injections; all other
experiments were done with 12-14 week old mice. The gsg-/- mouse lacks γ-SG due to
gene targeting, resulting in an additional loss of β- and δ-SG and a decrease of α-SG
(Hack et al., 1998), and were backcrossed for more than 10 generations onto the C57Bl/6
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strain. The dsg-/- mouse lacks δ-SG also due to gene targeting, resulting in an additional
loss of α-, β-, and γ-SG on a 129SvJ/129SvEms-+Ter/J background (Hack et al., 2000).
Mdx mice lacking dystrophin were obtained from The Jackson Laboratory (Bar Harbor,
ME), and were maintained as a colony of homozygous mutant animals (C57Bl/10
background strain).

In situ TA muscle mechanics
In situ muscle function was examined on the tibialis anterior (TA) using a
protocol developed from methods described previously (Dellorusso et al., 2001). Briefly,
mice were deeply anesthetized by i.p. injection of ketamine-xylazine (80 and 10 mg/kg),
with body temperature maintained at 37oC, and monitored throughout the experiment.
For each preparation, the distal tendon of the TA was carefully dissected and tied with
4.0 braided surgical silk. The sciatic nerve was exposed and all of its branches were cut
except for the common peroneal nerve. The foot was secured to a platform and the knee
immobilized using a stainless steel pin, with care taken not to interfere with the blood
supply to the muscles. The suture from the TA tendon was attached to the lever arm of a
305B dual-mode servomotortransducer (Aurora Scientific, Ontario, Canada). Isometric
muscle contractions were then elicited by stimulating the distal part of the sciatic nerve
via bipolar electrodes, using supramaximal square-wave pulses of 0.02 msec (701A
stimulator; Aurora Scientific). Data acquisition and control of the servomotor were
conducted using a Lab-View-based DMC program (version 5.202; Aurora Scientific).
Optimal muscle length (Lo) was determined by incrementally stretching the muscle until
the maximum isometric twitch force was achieved (Po). Muscle length was measured
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using digital calipers based on well-defined anatomical landmarks. Three maximum
isometric tetanic forces were acquired using a train of 150Hz, 500msec supramaximal
electrical pulses at the optimal length in the muscles and highest force was recorded. A 2minute resting period was allowed between each tetanic contraction. Following isometric
contractions, muscles were subjected to two eccentric contractions (ECC) with the
muscle stimulated at 150 Hz for a total of 300 ms. TA muscles were stretched 24% Lo in
the final 200 ms stimulation. The second ECC was administrated after a 10 s rest period
under the same parameters. Post-ECC muscle isometric forces were measured after 1min,
5min and 15 min. The drop in force between the isometric force during eccentric
contraction and recovery time served as an index of susceptibility to eccentric
contraction-induced injury.

Viral constructs and injections
Human γ-SG cDNA was utilized to generate recombinant adeno-associated virus
serotype 2/8 (rAAV) as described previously (Barton, 2010), and expression was
regulated by a truncated desmin promoter (Li et al., 1993).Vector production was
performed at the University of Pennsylvania Vector Core. Solutions containing 1 x 1011
viral particles diluted in 50µl of phosphate-buffered saline (PBS) were injected into the
anterior compartment of the lower hindlimbs of 3-week old gsg-/- mice, targeting the
tibialis anterior (TA) and extensor digitorum longus (EDL) muscles as described
previously. After injection, mice were housed in the animal facility until time of analysis,
1-month post-injection. The TA muscles were dissected and rapidly frozen in liquid
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nitrogen for biochemical analysis, while the EDL muscles were frozen in OCT (Sakura
Finetek, Torrance, CA) for immunohistochemical analysis.
Cytosolic/Nuclear Fractionation
Snap frozen TA muscles were ground using a mortar and pestle and processed as
described previously (Dimauro et al., 2012). In short, nuclear fractions were isolated by
lysates undergoing a series of centrifugations and resuspensions in STM buffer (250 mM
sucrose, 50 mM Tris-HCl pH 7.4, 5 mM MgCl2, protease and phosphatase inhibitors)
followed by resuspension in NET buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.5M
NaCl, 0.2 mM EDTA, 20% glycerol, 1% Triton-x-100, protease and phosphatase
inhibitors) and lysing of nuclei by passage though an 18-gauge needle and sonication.
Cytosolic fractions were isolated by centrifugation, precipitation in 100% acetone at 20oC for 1 hour, and resuspension in STM buffer. Processed lysates were then analyzed
by immunoblotting as described above.

C2C12 myotube culture
Flexible silicone membranes (Specialty Manufacturing, Inc.) were stretched
across the bottom of custom cylinders which acted as a culture chamber. The membranes
were held in place using an O-ring as described previously (He et al., 2004). Membranes
were then coated with a thin layer of 2 mg/mL GFR Matrigel (BD #354230). C2C12
myoblasts (3.5 × 105 / cylinder) were seeded onto the membranes and maintained at 5%
CO2 at 37°C in growth media (10% FBS, 100 U penicillin, 100 µg streptomycin, 100
µg/mL gentamycin in DMEM) for approximately 24 h until 70% to 80% confluent, then
switched to differentiation media (2% HS, 100 U penicillin, 100 µg streptomycin, 100
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µg/mL Gentamycin in DMEM). Myoblasts were allowed to differentiate into
multinucleated myotubes for 5 days, during which media was changed every other day
before stretching as described below.

Myotube stretching protocol
C2C12 myotubes were stretched using an apparatus that produces isotropic twodimensional strain of cells in vitro, as described previously (He et al., 2004). Briefly,
myotubes were subjected to 10% strain, 40 times per minute, for 30 min, at 37°C in a
humidified atmosphere of 5% CO2 in air. Control myotubes were treated identically but
were not stretched. Lysates were harvested immediately as described below. Primary
myotubes were stretched using the protocol described for C2C12 myotubes. Stretched
myotubes were then incubated without stretch for a further 1, 2, or 4 h at 37°C before
harvesting lysates for immunoblotting as described below. Control (non-stretched)
myotubes were harvested immediately after the end of the stretching protocol used for the
stretched myotubes.

In vitro EDL muscle mechanics
Mice were anaesthetized using ketamine and xylazine. EDL muscles were
dissected and placed in an organ bath containing oxygenated high-glucose (25 mM)
DMEM with HEPES (25 mM) (Life Technologies), at room temperature. For rapamycin
sensitivity experiments, high-glucose DMEM was supplemented with 150 nM rapamycin
(Sigma) or vehicle only (0.1% DMSO). Muscles were adjusted to 9.3 mN of resting
tension, approximately equivalent to optimal length, based on our previous experiments
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(Moorwood et al., 2013). After a 10-min equilibration period, the length of the muscle
was measured using calipers, and the muscle was subjected to a stretching protocol of
15% strain (held for 100 ms with ramp times of 50 ms), 20 times per minute, for either 30
or 90 min, using an in vitro muscle test system (Aurora Scientific). Muscles were snapfrozen immediately following the end of the stretch protocol. Contralateral muscles were
used as controls and were adjusted to the same length as the stretched muscles, then
incubated in oxygenated high-glucose DMEM with HEPES at room temperature for the
equivalent length of time, before snap-freezing.

SCH772984 Treatment
SCH772984 (Selleck Chemicals, S7101) was prepared in 20% HPβCD to pH 4.5,
then diluted in 20% HPβCD for dosing at 12.5mg/kg at 5mL/kg. 6-7 week old C57 and
gsg-/- mice were injected daily by i.p. injection for 5 consecutive days. Mice were
weighed prior to treatment, on day 3, and on day 5 before in situ TA mechanical
stimulation described above.

Statistics
Chapters 2+4: All results are shown as the means ± S.E.M. unless stated
otherwise. Statistical analyses of the data were performed using one-way or two-way
ANOVA followed by Bonferroni post hoc test. P-values of less than 0.05 were
considered statistically significant.
Chapter 3: Comparisons between non-stretched and stretched C2C12 cells
performed using unpaired Student’s t-test. Comparisons between C57 and gsg-/- muscles
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with and without rapamycin were performed by two-way ANOVA with Tukey’s multiple
comparisons test.
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